The Homeobox Genes: Classification, Regulation, Biological Functions, and Diseases

Abstract

Homeobox genes constitute a large family of transcription factors that act as master regulators involved in multiple fundamental processes such as development and cell differentiation. Consequently, these transcription factors perform diverse functions throughout human life. However, dysregulation of homeobox gene expression, through pathogenic variants or epigenetic alterations, has been increasingly associated with a wide range of human disorders. In particular, correlations between homeobox genes and various types of cancer have been documented in hundreds of studies. This review provides an integrative overview of homeobox gene biology, summarizing their classification as well as their physiological and pathological roles across noncancerous and cancerous diseases. Particular attention is given to how dysregulation of gene expression contributes to various noncancerous diseases (e.g., congenital, metabolic, and neurodegenerative disorders) and to malignancies, especially the five highest incidence of cancers, with a detailed focus on lung cancer, where epigenetic mechanisms play a central role in tumor progression.

Keywords

cancer / epigenetics / homeobox genes / lung cancer / noncancerous diseases / pathological variants

References

[1] S. Bhatlekar and J. Z. Fields, “Boman BM. HOX Genes and Their Role in the Development of human Cancers,” Journal of Molecular Medicine 92 (2014): 811–823.

[2] T. Rauch, Z. Wang, X. Zhang, et al., “Homeobox Gene Methylation in Lung Cancer Studied by Genome-wide Analysis With a Microarray-based Methylated CpG Island Recovery Assay,” Proceedings of the National Academy of Sciences of the United States of America 104, no. 13 (2007): 5527–5532.

[3] Y. Feng, T. Zhang, Y. Wang, et al., “Homeobox Genes in Cancers: From Carcinogenesis to Recent Therapeutic Intervention,” Frontiers in Oncology 11 (2021): 770428.

[4] M. P. Scott, “40 years of the Homeobox: Either It Is Wrong or It Is Quite Interesting,” Development (Cambridge, England) 151, no. 6 (2024): dev202776.

[5] Y.-F. Zhong and P. W. Holland, “The Dynamics of Vertebrate Homeobox Gene Evolution: Gain and Loss of Genes in Mouse and human Lineages,” BMC Evolutionary Biology 11 (2011): 1–13.

[6] P. W. Holland, H. A. F. Booth, and E. A. Bruford, “Classification and Nomenclature of all human Homeobox Genes,” BMC Biology 5, no. 1 (2007): 47.

[7] K. A. Hubert and D. M. Wellik, “Hox Genes in Development and Beyond,” Development (Cambridge, England) 150, no. 1 (2023): dev192476.

[8] C. Mio, F. Baldan, and G. Damante, “NK2 homeobox Gene Cluster: Functions and Roles in human Diseases,” Genes & Diseases 10, no. 5 (2023): 2038–2048.

[9] X. Fu and X. Zhu, “Key Homeobox Transcription Factors Regulate the Development of the Firefly's Adult Light Organ and Bioluminescence,” Nature Communications 15, no. 1 (2024): 1736.

[10] K. C. Wang, J. A. Helms, and H. Y. Chang, “Regeneration, Repair and Remembering Identity: The Three Rs of Hox Gene Expression,” Trends in Cell Biology 19, no. 6 (2009): 268–275.

[11] J. Steens and D. Klein, “HOX Genes in Stem Cells: Maintaining Cellular Identity and Regulation of Differentiation,” Frontiers in Cell and Developmental Biology 10 (2022): 1002909.

[12] R. Okino, Y. Goda, and Y. Ono, “The Hox-based Positional Memory in Muscle Stem Cells,” The Journal of Biochemistry 176, no. 4 (2024): 277–283.

[13] L. Pfeiferová, M. Španko, J. Šáchová, et al., “The HOX Code of human Adult Fibroblasts Reflects Their Ectomesenchymal or Mesodermal Origin,” Histochemistry and Cell Biology 163, no. 1 (2025): 38.

[14] V. Bradaschia-Correa, K. Leclerc, A. M. Josephson, et al., “Hox Gene Expression Determines Cell Fate of Adult Periosteal Stem/Progenitor Cells,” Scientific Reports 9, no. 1 (2019): 5043.

[15] J. Liu, G. Lang, and J. Shi, “Epigenetic Regulation of PDX-1 in Type 2 Diabetes Mellitus,” Diabetes, Metabolic Syndrome and Obesity (2021): 431–442.

[16] P. Le Tanno, J. Breton, and M. Bidart, “PBX1 haploinsufficiency Leads to Syndromic Congenital Anomalies of the Kidney and Urinary Tract (CAKUT) in Humans,” Journal of Medical Genetics 54, no. 7 (2017): 502–510.

[17] Y. Wang, J. Gao, Z. Ren, et al., “A Pan-cancer Analysis of homeobox family: Expression Characteristics and Latent Significance in Prognosis and Immune Microenvironment,” Frontiers in Oncology 15 (2025): 1521652.

[18] C. Yadav, R. Yadav, S. Nanda, S. Ranga, P. Ahuja, and M. Tanwar, “Role of HOX Genes in Cancer Progression and Their Therapeutical Aspects,” Gene (2024): 148501.

[19] X. Hu, Y. Wang, X. Zhang, et al., “DNA Methylation of HOX Genes and Its Clinical Implications in Cancer,” Experimental and Molecular Pathology 134 (2023): 104871.

[20] P. W. Holland, H. A. F. Booth, and E. A. Bruford, “Classification and Nomenclature of all human Homeobox Genes,” BMC Biology 5 (2007): 1–28.

[21] R. Caspa Gokulan, L. F. Yap, and I. C. Paterson, “HOPX: A Unique Homeodomain Protein in Development and Tumor Suppression,” Cancers 14, no. 11 (2022): 2764.

[22] K. Mukherjee, L. Brocchieri, and T. R. Bürglin, “A Comprehensive Classification and Evolutionary Analysis of Plant Homeobox Genes,” Molecular Biology and Evolution 26, no. 12 (2009): 2775–2794.

[23] D. E. Ferrier, “The Origin of the Hox/ParaHox Genes, the Ghost Locus Hypothesis and the Complexity of the First Animal,” Briefings in Functional Genomics 15, no. 5 (2016): 333–341.

[24] C. Minguillón and J. Garcia-Fernàndez, “Genesis and Evolution of the Evx and Mox Genes and the Extended Hox and ParaHox Gene Clusters,” Genome Biology 4, no. 2 (2003): R12.

[25] V. P. Rawat, R. K. Humphries, and C. Buske, “Beyond Hox: The Role of ParaHox Genes in Normal and Malignant Hematopoiesis,” Blood, The Journal of the American Society of Hematology 120, no. 3 (2012): 519–527.

[26] M. Truong, B. Yang, J. Wagner, et al., “Even-skipped Homeobox 1 Is Frequently Hypermethylated in Prostate Cancer and Predicts PSA Recurrence,” British Journal of Cancer 107, no. 1 (2012): 100–107.

[27] M.-A. Sun, H. Fan, S. Ralls, et al., “The Homeobox Transcription Factor MNX1 Regulates the Expression of Many Non-MN-specific Neuronal Genes in Motor Neurons,” Nucleic Acids Research 53, no. 19 (2025): gkaf1015.

[28] G. Zeng, X. Liu, X. Su, et al., “The Role of MEOX1 in Non-neoplastic and Neoplastic Diseases,” Biomedicine & Pharmacotherapy 158 (2023): 114068.

[29] B. Zhang, X. Li, X. Qian, and J. Tang, “De Novo Variant in GBX1 Gene Associated with Developmental Delay and Focal Epilepsy,” Molecular Genetics & Genomic Medicine 13, no. 6 (2025): e70114.

[30] N. Ebrahim, K. Shakirova, and E. Dashinimaev, “PDX1 is the Cornerstone of Pancreatic β-cell Functions and Identity,” Frontiers in Molecular Biosciences 9 (2022): 1091757.

[31] M. Coskun, J. T. Troelsen, and O. H. Nielsen, “The Role of CDX2 in Intestinal Homeostasis and Inflammation,” Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1812, no. 3 (2011): 283–289.

[32] R. Chellappa, S. Li, S. Pauley, I. Jahan, K. Jin, and M. Xiang, “Barhl1 regulatory Sequences Required for Cell-specific Gene Expression and Autoregulation in the Inner Ear and central Nervous System,” Molecular and Cellular Biology 28, no. 6 (2008): 1905–1914.

[33] X. Huang, Z. Wang, J. Zhang, et al., “BARX1 promotes Osteosarcoma Cell Proliferation and Invasion by Regulating HSPA6 Expression,” Journal of Orthopaedic Surgery and Research 18, no. 1 (2023): 211.

[34] J. L. Rubenstein and A. S. Nord, “Ekker M. DLX Genes and Proteins in Mammalian Forebrain Development,” Development (Cambridge, England) 151, no. 11 (2024): dev202684.

[35] J. Liang, J. Von den Hoff, J. Lange, Y. Ren, Z. Bian, and C. E. Carels, “MSX1 mutations and Associated Disease Phenotypes: Genotype-phenotype Relations,” European Journal of Human Genetics 24, no. 12 (2016): 1663–1670.

[36] C. Cao, L. Li, Q. Zhang, et al., “Nkx2. 5: A Crucial Regulator of Cardiac Development, Regeneration and Diseases,” Frontiers in Cardiovascular Medicine 10 (2023): 1270951.

[37] Y. El Fersioui, G. Pinton, N. Allaman-Pillet, and D. F. Schorderet, “Hmx1 regulates urfh1 Expression in the Craniofacial Region in Zebrafish,” PLoS ONE 16, no. 1 (2021): e0245239.

[38] P. Cheng, G. Wang, Y. Song, and Y. An, “Novel Association of LBX1 Mutation With Tetralogy of Fallot and Hypertrophic Cardiomyopathy: Implications for Cardiac Development,” Scientific Reports 14, no. 1 (2024): 26179.

[39] N. Kim, K. W. Min, K. H. Kang, et al., “Regulation of Retinal Axon Growth by Secreted Vax1 Homeodomain Protein,” Elife 3 (2014): e02671.

[40] A. R. Leitoguinho, E. Ng, E. Stanley, and A. Elefanty, “The Role of Ventx Homeobox Gene During human Haematopoietic Development,” Experimental Hematology 76 (2019): S73.

[41] J. T. Jackson, S. L. Nutt, and M. P. McCormack, “The Haematopoietically-expressed Homeobox Transcription Factor: Roles in Development, Physiology and Disease,” Frontiers in Immunology 14 (2023): 1197490.

[42] A. Beckers, L. Alten, C. Viebahn, P. Andre, and A. Gossler, “The Mouse Homeobox Gene Noto Regulates Node Morphogenesis, Notochordal Ciliogenesis, and Left–right Patterning,” Proceedings of the National Academy of Sciences of the United States of America 104, no. 40 (2007): 15765–15770.

[43] V. Sivakamasundari, P. Kraus, W. Sun, et al., “A Developmental Transcriptomic Analysis of Pax1 and Pax9 in Embryonic Intervertebral Disc Development,” Biology Open 6, no. 2 (2017): 187–199.

[44] A. Terrinoni, G. Micheloni, V. Moretti, et al., “OTX Genes in Adult Tissues,” International Journal of Molecular Sciences 24, no. 23 (2023): 16962.

[45] C. Zhang, X. Chen, Y. Chen, et al., “The PITX Gene family as Potential Biomarkers and Therapeutic Targets in Lung Adenocarcinoma,” Medicine 100, no. 4 (2021): e23936.

[46] N. Li, Y. Zeng, and J. Huang, “Signaling Pathways and Clinical Application of RASSF1A and SHOX2 in Lung Cancer,” Journal of Cancer Research and Clinical Oncology 146 (2020): 1379–1393.

[47] K. U. Schneider, D. Dietrich, M. Fleischhacker, et al., “Correlation of SHOX2 Gene Amplification and DNA Methylation in Lung Cancer Tumors,” BMC Cancer 11 (2011): 1–9.

[48] P. P. Iyyanar, Z. Wu, Y. Lan, Y.-C. Hu, and R. Jiang, “Alx1 deficient Mice Recapitulate Craniofacial Phenotype and Reveal Developmental Basis of ALX1-related Frontonasal Dysplasia,” Frontiers in Cell and Developmental Biology 10 (2022): 777887.

[49] Y. Zhao, H. Zhou, K. Ma, et al., “Abnormal Methylation of Seven Genes and Their Associations With Clinical Characteristics in Early Stage Non-small Cell Lung Cancer,” Oncology Letters 5, no. 4 (2013): 1211–1218.

[50] A. Pattyn, X. Morin, H. Cremer, C. Goridis, and J.-F. Brunet, “Expression and Interactions of the Two Closely Related Homeobox Genes Phox2a and Phox2b During Neurogenesis,” Development (Cambridge, England) 124, no. 20 (1997): 4065–4075.

[51] A. L.-Y. Pang, M. M. Martin, A. L. Martin, and W.-Y. Chan, “Molecular Basis of Diseases of the Endocrine system,” Molecular Pathology. (Elsevier, 2009): 435–463.

[52] M. Le Beulze, C. Daubech, A. Balde-Camara, F. Ghieh, and F. Vialard, “Mammal Reproductive Homeobox (Rhox) Genes: An Update of Their Involvement in Reproduction and Development,” Genes 14, no. 9 (2023): 1685.

[53] E. Madissoon, E.-M. Jouhilahti, L. Vesterlund, et al., “Characterization and Target Genes of Nine human PRD-Like Homeobox Domain Genes Expressed Exclusively in Early Embryos,” Scientific Reports 6, no. 1 (2016): 28995.

[54] Q. Wang and X. Qiu. Comprehensive Analysis of the Expression and Prognosis for IRXs in Non-small Cell Lung Cancer. (2020).

[55] O. Machon, J. Masek, O. Machonova, S. Krauss, and Z. Kozmik, “Meis2 is Essential for Cranial and Cardiac Neural Crest Development,” BMC Developmental Biology 15, no. 1 (2015): 40.

[56] Y. Wang, Q. Qin, Z. Wang, et al., “The Mohawk Homeobox Gene Represents a Marker and Osteo-inhibitory Factor in Calvarial Suture Osteoprogenitor Cells,” Cell Death & Disease 15, no. 6 (2024): 420.

[57] L. Crisafulli, M. Brindisi, M. G. Liturri, C. Sobacchi, and F. Ficara, “PBX1: A TALE of Two Seasons—key Roles During Development and in Cancer,” Frontiers in Cell and Developmental Biology 12 (2024): 1372873.

[58] E. Longobardi, G. Iotti, P. Di Rosa, et al., “Prep1 (pKnox1)-deficiency Leads to Spontaneous Tumor Development in Mice and Accelerates EµMyc Lymphomagenesis: A Tumor Suppressor Role for Prep1,” Molecular Oncology 4, no. 2 (2010): 126–134.

[59] S. E. Powers, K. Taniguchi, and W. Yen, “Tgif1 and Tgif2 Regulate Nodal Signaling and Are Required for Gastrulation,” Development (Cambridge, England) 137, no. 2 (2010): 249–259.

[60] R. D. Mullen, S. C. Colvin, C. S. Hunter, et al., “Roles of the LHX3 and LHX4 LIM-homeodomain Factors in Pituitary Development,” Molecular and Cellular Endocrinology 265 (2007): 190–195.

[61] L. W. Harries, J. E. Brown, and A. L. Gloyn, “Species-specific Differences in the Expression of the HNF1A, HNF1B and HNF4A Genes,” PLoS ONE 4, no. 11 (2009): e7855.

[62] H. Oppermann, E. Marcos-Grañeda, and L. A. Weiss, “CUX1-related Neurodevelopmental Disorder: Deep Insights Into Phenotype-genotype Spectrum and Underlying Pathology,” European Journal of Human Genetics 31, no. 11 (2023): 1251–1260.

[63] S. Heller, Z. Li, Q. Lin, et al., “Transcriptional Changes and the Role of ONECUT1 in hPSC Pancreatic Differentiation,” Communications Biology 4, no. 1 (2021): 1298.

[64] O. Panchal, G. Wichmann, R. Grenman, et al., “SATB1 as Oncogenic Driver and Potential Therapeutic Target in Head & Neck Squamous Cell Carcinoma (HNSCC),” Scientific Reports 10, no. 1 (2020): 8615.

[65] A. Stergiopoulos, M. Elkouris, and P. K. Politis, “Prospero-related Homeobox 1 (Prox1) at the Crossroads of Diverse Pathways During Adult Neural Fate Specification,” Frontiers in Cellular Neuroscience 8 (2015): 454.

[66] T. De Andrade, L. Moreira, A. Duarte, et al., “Expression of New Red Cell–related Genes in Erythroid Differentiation,” Biochemical Genetics 48, no. 1 (2010): 164–171.

[67] P. Dubot, F. Sabourdy, J. Rybova, J. A. Medin, and T. Levade, “Inherited Monogenic Defects of Ceramide Metabolism: Molecular Bases and Diagnoses,” Clinica Chimica Acta 495 (2019): 457–466.

[68] T. Shaw, F. G. Barr, and A. Üren, “The PAX Genes: Roles in Development, Cancer, and Other Diseases,” Cancers 16, no. 5 (2024): 1022.

[69] S. Jiang, T. Wang, Y. Han, et al., “Downregulation of Homeobox B8 in Attenuating Non-small Cell Lung Cancer Cell Migration and Invasion Though the Epithelial-mesenchymal Transition Pathway,” Translational Cancer Research 13, no. 1 (2024): 413.

[70] M. A. Kulakova, G. P. Maslakov, and L. O. Poliushkevich, “Irreducible Complexity of Hox Gene: Path to the Canonical Function of the Hox Cluster,” Biochemistry (Moscow) 89, no. 6 (2024): 987–1001.

[71] U. S. Shenoy, D. Adiga, S. P. Kabekkodu, K. D. Hunter, and R. Radhakrishnan, “Molecular Implications of HOX Genes Targeting Multiple Signaling Pathways in Cancer,” Cell Biology and Toxicology (2022): 1–30.

[72] S. Papageorgiou, “Comparison of Models for the Collinearity of Hox Genes in the Developmental Axes of Vertebrates,” Current Genomics 13, no. 3 (2012): 245–251.

[73] M. Wei, Z. Qin, D. Kong, et al., “Echiuran Hox Genes Provide New Insights Into the Correspondence Between Hox Subcluster Organization and Collinearity Pattern,” Proceedings of the Royal Society B 289, no. 1982 (2022): 20220705.

[74] Y. Zhou, Q. Wu, and Y. Guo, “Deciphering the Emerging Landscape of HOX Genes in Cardiovascular Biology, Atherosclerosis and Beyond,” International Journal of Molecular Medicine 53, no. 2 (2024): 1–12.

[75] M. G. El-Sisi, S. M. Radwan, S. S. Ali, M. Y. Mostafa, and N. M. Hamdy, “The Long Antisense Non-coding RNA HOXA Transcript at the Distal Tip (LncRNA HOTTIP) in Health and Disease: A Comprehensive Review and in Silico Analysis,” Naunyn-Schmiedeberg's Archives of Pharmacology 398, no. 12 (2025): 16537–16575.

[76] J. Wang, Z. Su, S. Lu, et al., “LncRNA HOXA-AS2 and Its Molecular Mechanisms in human Cancer,” Clinica Chimica Acta 485 (2018): 229–233.

[77] Z. X. Chong, W. Y. Ho, and S. K. Yeap, “Tumour-regulatory Role of Long Non-coding RNA HOXA-AS3,” Progress in Biophysics and Molecular Biology 189 (2024): 13–25.

[78] R. Mamillapalli, N. Gawde, M. Fay, R. Atwani, I. Moridi, and H. S. Taylor, “The Role of Long Non-coding Ribonucleic Acid HOXA11-AS in Endometriosis Therapy,” Reproductive Biology and Endocrinology 23, no. 1 (2025): 83.

[79] Y. Jing, X. Jiang, L. Lei, et al., “Mutant NPM1-regulated lncRNA HOTAIRM1 Promotes Leukemia Cell Autophagy and Proliferation by Targeting EGR1 and ULK3,” Journal of Experimental & Clinical Cancer Research 40, no. 1 (2021): 312.

[80] S. Al-Kershi, R. Bhayadia, M. Ng, et al., “The Stem Cell–specific Long Noncoding RNA HOXA10-AS in the Pathogenesis of KMT2A-rearranged Leukemia,” Blood Advances 3, no. 24 (2019): 4252–4263.

[81] X. Hu, Y. Wang, S. Zhang, X. Gu, X. Zhang, and L. Li, “LncRNA HOXA10-AS as a Novel Biomarker and Therapeutic Target in human Cancers,” Frontiers in Molecular Biosciences 11 (2025): 1520498.

[82] T. R. Lappin, D. G. Grier, A. Thompson, and H. L. Halliday, “HOX Genes: Seductive Science, Mysterious Mechanisms,” The Ulster Medical Journal 75, no. 1 (2006): 23.

[83] G. Zhu, H. Luo, Y. Feng, et al., “HOXBLINC Long Non-coding RNA Activation Promotes Leukemogenesis in NPM1-mutant Acute Myeloid Leukemia,” Nature Communications 12, no. 1 (2021): 1956.

[84] J. Wu, J. Yu, H. Zhu, et al., “LncRNA HOXB-AS3 Promotes Proliferation, Migration, and Invasion of Gallbladder Cancer Cells by Activating the MEK/ERK Pathway,” Heliyon 10, no. 16 (2024): e35906.

[85] C. Nepal, A. Taranta, Y. Hadzhiev, et al., “Ancestrally Duplicated Conserved Noncoding Element Suggests Dual Regulatory Roles of HOTAIR in Cis and Trans,” Iscience 23, no. 4 (2020): 101008.

[86] X.-Y. Tao, Q.-Q. Li, S.-S. Dong, et al., “Long Noncoding HOXD-AS1: A Crucial Regulator of Malignancy,” Frontiers in Cell and Developmental Biology 13 (2025): 1543915.

[87] M. Yu, J. Zhan, and H. Zhang, “HOX family Transcription Factors: Related Signaling Pathways and Post-translational Modifications in Cancer,” Cellular Signalling 66 (2020): 109469.

[88] E. M. Collins and A. Thompson, “HOX Genes in Normal, Engineered and Malignant Hematopoiesis,” International Journal of Developmental Biology 62, no. 11-12 (2018): 847–856.

[89] J. F. Kribelbauer, R. E. Loker, S. Feng, et al., “Context-dependent Gene Regulation by Homeodomain Transcription Factor Complexes Revealed by Shape-readout Deficient Proteins,” Molecular Cell 78, no. 1 (2020): 152–167. e11.

[90] X. Wang, C. He, and X. Hu, “LIM Homeobox Transcription Factors, a Novel Subfamily Which Plays an Important Role in Cancer,” Oncology Reports 31, no. 5 (2014): 1975–1985.

[91] M. Srivastava, C. Larroux, D. R. Lu, et al., “Early Evolution of the LIM Homeobox Gene family,” BMC Biology 8 (2010): 1–13.

[92] J. Yu, D. Liu, X. Sun, et al., “CDX2 inhibits the Proliferation and Tumor Formation of Colon Cancer Cells by Suppressing Wnt/β-catenin Signaling via Transactivation of GSK-3β and Axin2 Expression,” Cell Death & Disease 10, no. 1 (2019): 26.

[93] K. Salari, M. E. Spulak, J. Cuff, et al., “CDX2 is an Amplified Lineage-survival Oncogene in Colorectal Cancer,” Proceedings of the National Academy of Sciences of the United States of America 109, no. 46 (2012): E3196–E3205.

[94] V. Töhönen, S. Katayama, L. Vesterlund, et al., “Novel PRD-Like Homeodomain Transcription Factors and Retrotransposon Elements in Early human Development,” Nature Communications 6, no. 1 (2015): 8207.

[95] E.-M. Jouhilahti, E. Madissoon, L. Vesterlund, et al., “The human PRD-Like Homeobox Gene LEUTX Has a central Role in Embryo Genome Activation,” Development (Cambridge, England) 143, no. 19 (2016): 3459–3469.

[96] G. Levi, N. Narboux-Nême, and M. Cohen-Solal, “DLX Genes in the Development and Maintenance of the Vertebrate Skeleton: Implications for human Pathologies,” Cells 11, no. 20 (2022): 3277.

[97] D. Lang, S. K. Powell, R. S. Plummer, K. P. Young, and B. A. Ruggeri, “PAX Genes: Roles in Development, Pathophysiology, and Cancer,” Biochemical Pharmacology 73, no. 1 (2007): 1–14.

[98] G. D. Marconi, L. Fonticoli, T. S. Rajan, et al., “Epithelial-mesenchymal Transition (EMT): The Type-2 EMT in Wound Healing, Tissue Regeneration and Organ Fibrosis,” Cells 10, no. 7 (2021): 1587.

[99] S. Tomida, K. Yanagisawa, K. Koshikawa, et al., “Identification of a Metastasis Signature and the DLX4 Homeobox Protein as a Regulator of Metastasis by Combined Transcriptome Approach,” Oncogene 26, no. 31 (2007): 4600–4608.

[100] Y. Huang, K. Sitwala, J. Bronstein, et al., “Identification and Characterization of Hoxa9 Binding Sites in Hematopoietic Cells,” Blood, The Journal of the American Society of Hematology 119, no. 2 (2012): 388–398.

[101] C. M. Ferrell, S. T. Dorsam, H. Ohta, et al., “Activation of Stem-cell Specific Genes by HOXA9 and HOXA10 Homeodomain Proteins in CD34+ human Cord Blood Cells,” Stem Cells 23, no. 5 (2005): 644–655.

[102] M. Oshima, M. Endoh, T. A. Endo, et al., “Genome-wide Analysis of Target Genes Regulated by HoxB4 in Hematopoietic Stem and Progenitor Cells Developing From Embryonic Stem Cells,” Blood, The Journal of the American Society of Hematology 117, no. 15 (2011): e142–e150.

[103] A. Fessner, J. S. Esser, F. Bluhm, et al., “The Transcription Factor HoxB5 Stimulates Vascular Remodelling in a Cytokine-dependent Manner,” Cardiovascular Research 101, no. 2 (2014): 247–255.

[104] H. Al Sadoun, M. Burgess, K. E. Hentges, and K. A. Mace, “Enforced Expression of Hoxa3 Inhibits Classical and Promotes Alternative Activation of Macrophages in Vitro and in Vivo,” The Journal of Immunology 197, no. 3 (2016): 872–884.

[105] J. H. Kuo, I. Cuevas, A. Chen, A. Dunn, M. Kuri, and N. Boudreau, “Secreted HoxA3 Promotes Epidermal Proliferation and Angiogenesis in Genetically Modified Three-dimensional Composite Skin Constructs,” Advances in Wound Care 3, no. 10 (2014): 605–613.

[106] B. He, Z. L. Ni, S. B. Kong, J. H. Lu, and H. B. Wang, “Homeobox Genes for Embryo Implantation: From Mouse to human,” Animal Models and Experimental Medicine 1, no. 1 (2018): 14–22.

[107] D. Huang, G. Guo, P. Yuan, et al., “The Role of Cdx2 as a Lineage Specific Transcriptional Repressor for Pluripotent Network During the First Developmental Cell Lineage Segregation,” Scientific Reports 7, no. 1 (2017): 17156.

[108] N. Makki and M. R. Capecchi, “Identification of Novel Hoxa1 Downstream Targets Regulating Hindbrain, Neural Crest and Inner Ear Development,” Developmental Biology 357, no. 2 (2011): 295–304.

[109] S. M. Hrycaj, B. R. Dye, N. C. Baker, et al., “Hox5 genes Regulate the Wnt2/2b-Bmp4-signaling Axis During Lung Development,” Cell Reports 12, no. 6 (2015): 903–912.

[110] K. A. Mace, S. L. Hansen, C. Myers, D. M. Young, and N. Boudreau, “HOXA3 induces Cell Migration in Endothelial and Epithelial Cells Promoting Angiogenesis and Wound Repair,” Journal of Cell Science 118, no. 12 (2005): 2567–2577.

[111] H. Yang, Y. Liang, Y. Cao, Y. Cao, and Z. Fan, “Homeobox C8 Inhibited the Osteo-/Dentinogenic Differentiation and Migration Ability of Stem Cells of the Apical Papilla via Activating KDM1A,” Journal of Cellular Physiology 235, no. 11 (2020): 8432–8445.

[112] Q. Wu, L. Zhang, P. Su, et al., “MSX2 mediates Entry of human Pluripotent Stem Cells Into Mesendoderm by Simultaneously Suppressing SOX2 and Activating NODAL Signaling,” Cell Research 25, no. 12 (2015): 1314–1332.

[113] G. Levi and Y. Gitton, “Dlx Genes and the Maintenance of Bone Homeostasis and Skeletal Integrity,” Cell Death & Differentiation 21, no. 9 (2014): 1345–1346.

[114] M. Q. Hassan, R. S. Tare, S. H. Lee, et al., “BMP2 commitment to the Osteogenic Lineage Involves Activation of Runx2 by DLX3 and a Homeodomain Transcriptional Network,” Journal of Biological Chemistry 281, no. 52 (2006): 40515–40526.

[115] K. Hosokawa, H. Ishimaru, T. Watanabe, and M. Fujimuro, “Pax5 mediates the Transcriptional Activation of the CD81 Gene,” Scientific Reports 11, no. 1 (2021): 22919.

[116] G. J. Liu, M. Jaritz, M. Wöhner, et al., “Repression of the B Cell Identity Factor Pax5 Is Not Required for Plasma Cell Development,” Journal of Experimental Medicine 217, no. 11 (2020): e20200147.

[117] R. Revilla-i-Domingo, I. Bilic, B. Vilagos, et al., “The B-cell Identity Factor Pax5 Regulates Distinct Transcriptional Programmes in Early and Late B Lymphopoiesis,” The EMBO Journal 31, no. 14 (2012): 3130–3146.

[118] M. Liu, Y. Xing, J. Tan, et al., “Comprehensive Summary: The Role of PBX1 in Development and Cancers,” Frontiers in Cell and Developmental Biology 12 (2024): 1442052.

[119] J. Zeng, D. Yi, W. Sun, et al., “Overexpression of HOXA9 Upregulates NF-κB Signaling to Promote human Hematopoiesis and Alter the Hematopoietic Differentiation Potentials,” Cell Regeneration 10, no. 1 (2021): 9.

[120] S. Paina, D. Garzotto, S. DeMarchis, et al., “Wnt5a is a Transcriptional Target of Dlx Homeogenes and Promotes Differentiation of Interneuron Progenitors in Vitro and in Vivo,” Journal of Neuroscience 31, no. 7 (2011): 2675–2687.

[121] P.-S. Hou, C.-Y. Chuang, C.-F. Kao, et al., “LHX2 regulates the Neural Differentiation of human Embryonic Stem Cells via Transcriptional Modulation of PAX6 and CER1,” Nucleic Acids Research 41, no. 16 (2013): 7753–7770.

[122] A. Iulianella, M. Sharma, M. Durnin, G. B. Vanden Heuvel, and P. A. Trainor, “Cux2 (Cutl2) integrates Neural Progenitor Development With Cell-cycle Progression During Spinal Cord Neurogenesis,” Development (Cambridge, England) 35, no. 4 (2008): 729–741.

[123] K. Harada, T. Yamazaki, C. Iwata, et al., “Identification of Targets of Prox1 During in Vitro Vascular Differentiation From Embryonic Stem Cells: Functional Roles of HoxD8 in Lymphangiogenesis,” Journal of Cell Science 122, no. 21 (2009): 3923–3930.

[124] T. Bruhl, C. Urbich, D. Aicher, A. Acker-Palmer, A. M. Zeiher, and S. Dimmeler, “Homeobox A9 Transcriptionally Regulates the EphB4 Receptor to Modulate Endothelial Cell Migration and Tube Formation,” Circulation Research 94, no. 6 (2004): 743–751.

[125] S. Winnik, M. Klinkert, H. Kurz, et al., “HoxB5 induces Endothelial Sprouting in Vitro and Modifies Intussusceptive Angiogenesis in Vivo Involving Angiopoietin-2,” Cardiovascular Research 83, no. 3 (2009): 558–565.

[126] H. Nakahara, A. Hasegawa, K. Otabe, et al., “Transcription Factor Mohawk and the Pathogenesis of human Anterior Cruciate Ligament Degradation,” Arthritis & Rheumatism 65, no. 8 (2013): 2081–2089.

[127] V. Raman, A. Tamori, M. Vali, K. Zeller, D. Korz, and S. Sukumar, “HOXA5 regulates Expression of the Progesterone Receptor,” Journal of Biological Chemistry 275, no. 34 (2000): 26551–26555.

[128] L. Li, D. Zhang, and X. Cao, “EBF1, PAX5, and MYC: Regulation on B Cell Development and Association With Hematologic Neoplasms,” Frontiers in Immunology 15 (2024): 1320689.

[129] L. Zhu, C. Chen, S. Wu, et al., “PAX6–WNK2 Axis Governs Corneal Epithelial Homeostasis,” Investigative Ophthalmology & Visual Science 65, no. 12 (2024): 40–40.

[130] A. N. Mardaryev, N. Meier, K. Poterlowicz, et al., “Lhx2 differentially Regulates Sox9, Tcf4 and Lgr5 in Hair Follicle Stem Cells to Promote Epidermal Regeneration After Injury,” Development (Cambridge, England) 138, no. 22 (2011): 4843–4852.

[131] D. Su, T. Krongbaramee, S. Swearson, et al., “Irx1 mechanisms for Oral Epithelial Basal Stem Cell Plasticity During Reepithelialization After Injury,” JCI Insight 10, no. 1 (2025): e179815.

[132] S. Jahan, N. Awaja, B. Hess, S. Hajjar, S. Sad, and D. Lohnes, “The Transcription Factor Cdx2 Regulates Inflammasome Activity Through Expression of the NLRP3 Suppressor TRIM31 to Maintain Intestinal Homeostasis,” Journal of Biological Chemistry 298, no. 10 (2022): 102386.

[133] S. Kachgal, K. A. Mace, and N. J. Boudreau, “The Dual Roles of Homeobox Genes in Vascularization and Wound Healing,” Cell Adhesion & Migration 6, no. 6 (2012): 457–470.

[134] M. P. Jimenez-García, A. Lucena-Cacace, D. Otero-Albiol, and A. Carnero, “Regulation of Sarcomagenesis by the Empty Spiracles Homeobox Genes EMX1 and EMX2,” Cell Death & Disease 12, no. 6 (2021): 515.

[135] X. Liu, J. Zhang, T. Yi, et al., “Decoding Tumor Angiogenesis: Pathways, Mechanisms, and Future Directions in Anti-cancer Strategies,” Biomarker Research 13, no. 1 (2025): 62.

[136] N. Alfaidy, S. Brouillet, G. Rajaraman, et al., “The Emerging Role of the Prokineticins and Homeobox Genes in the Vascularization of the Placenta: Physiological and Pathological Aspects,” Frontiers in Physiology 11 (2020): 591850.

[137] S. Contarelli, V. Fedele, and D. Melisi, “HOX Genes family and Cancer: A Novel Role for Homeobox B9 in the Resistance to Anti-angiogenic Therapies,” Cancers 12, no. 11 (2020): 3299.

[138] K. Kopec, D. Quaranto, N. R. DeSouza, et al., “The HOX Gene Family's Role as Prognostic and Diagnostic Biomarkers in Hematological and Solid Tumors,” Cancers 17, no. 2 (2025): 262.

[139] G. Li, J. Gao, P. Ding, and Y. Gao, “The Role of Endothelial Cell–pericyte Interactions in Vascularization and Diseases,” Journal of Advanced Research 67 (2025): 269–288.

[140] Y. Wu, M. Moser, V. L. Bautch, and C. Patterson, “HoxB5 is an Upstream Transcriptional Switch for Differentiation of the Vascular Endothelium From Precursor Cells,” Molecular and Cellular Biology 23, no. 16 (2003): 5680–5691.

[141] K. Scarlett, V. Pattabiraman, P. Barnett, D. Liu, and L. M. Anderson, “The Proangiogenic Effect of Iroquois Homeobox Transcription Factor Irx3 in human Microvascular Endothelial Cells,” Journal of Biological Chemistry 290, no. 10 (2015): 6303–6315.

[142] S. B. Bahrami, M. Veiseh, A. A. Dunn, and N. J. Boudreau, “Temporal Changes in Hox Gene Expression Accompany Endothelial Cell Differentiation of Embryonic Stem Cells,” Cell Adhesion & Migration 5, no. 2 (2011): 133–141.

[143] K. Rhoads, G. Arderiu, A. Charboneau, S. L. Hansen, W. Hoffman, and N. Boudreau, “A Role for Hox A5 in Regulating Angiogenesis and Vascular Patterning,” Lymphatic Research and Biology 3, no. 4 (2005): 240–252.

[144] J. Li and S. Gao, “HOXB5‑activated ANGPT2 Promotes the Proliferation, Migration, Invasion and Angiogenic Effect of Esophageal Cancer Cells via Activating ERK/AKT Signaling Pathway,” Experimental and Therapeutic Medicine 24, no. 3 (2022): 1–11.

[145] Z. Tan, K. Chen, W. Wu, et al., “Overexpression of HOXC10 Promotes Angiogenesis in human Glioma via Interaction With PRMT5 and Upregulation of VEGFA Expression,” Theranostics 8, no. 18 (2018): 5143.

[146] B. Trinh, S. Y. Ko, D. Haria, N. Barengo, and H. Naora, “The Homeoprotein DLX4 Controls Inducible Nitric Oxide Synthase-mediated Angiogenesis in Ovarian Cancer,” Molecular Cancer 14, no. 1 (2015): 97.

[147] L. Wang, H. Sun, L. Cao, and J. Wang, “Role of HOXA1-4 in the Development of Genetic and Malignant Diseases,” Biomarker Research 12, no. 1 (2024): 18.

[148] Z. Luo, S. K. Rhie, and P. J. Farnham, “The Enigmatic HOX Genes: Can We Crack Their Code?,” Cancers 11, no. 3 (2019): 323.

[149] B. Li, Q. Huang, and G.-H. Wei, “The Role of HOX Transcription Factors in Cancer Predisposition and Progression,” Cancers 11, no. 4 (2019): 528.

[150] N. Shah and S. Sukumar, “The Hox Genes and Their Roles in Oncogenesis,” Nature Reviews Cancer 10, no. 5 (2010): 361–371.

[151] S. Merabet and R. S. Mann, “To be Specific or Not: The Critical Relationship Between Hox and TALE Proteins,” Trends in Genetics 32, no. 6 (2016): 334–347.

[152] J. Smith, A. Zyoud, and C. Allegrucci, “A Case of Identity: HOX Genes in Normal and Cancer Stem Cells,” Cancers 11, no. 4 (2019): 512.

[153] P. B. Pinto, K. Domsch, and I. Lohmann, Hox Function and Specificity–A Tissue Centric View. (Elsevier, 2024): 35–43.

[154] S. Bhatlekar, J. Z. Fields, and B. M. Boman, “Role of HOX Genes in Stem Cell Differentiation and Cancer,” Stem Cells International 2018 (2018): 3569493.

[155] A. Seifert, D. F. Werheid, S. M. Knapp, and E. Tobiasch, “Role of Hox Genes in Stem Cell Differentiation,” World Journal of Stem Cells 7, no. 3 (2015): 583.

[156] T. R. Bürglin, Homeodomain Subtypes and Functional Diversity. A Handbook of Transcription Factors. (Springer, 2011): 95–122.

[157] B. De Kumar and D. C. Darland, “The Hox Protein Conundrum: The,” Developmental Biology 477 (2021): 284–292.

[158] D. K. Papadopoulos, V. Vukojević, Y. Adachi, L. Terenius, R. Rigler, and W. J. Gehring, “Function and Specificity of Synthetic Hox Transcription Factors in Vivo,” Proceedings of the National Academy of Sciences of the United States of America 107, no. 9 (2010): 4087–4092.

[159] J. Liu, Q. Xiao, and J. Xiao, “Wnt/β-catenin Signalling: Function, Biological Mechanisms, and Therapeutic Opportunities,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 3.

[160] Z. Deng, T. Fan, and C. Xiao, “TGF-β Signaling in Health, Disease, and Therapeutics,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 61.

[161] Q. Guo, Y. Jin, and X. Chen, “NF-κB in Biology and Targeted Therapy: New Insights and Translational Implications,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 53.

[162] X. Hu, J. Li, M. Fu, X. Zhao, and W. Wang, “The JAK/STAT Signaling Pathway: From Bench to Clinic,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 402.

[163] L. Cambier, M. Plate, H. M. Sucov, and M. Pashmforoush, “Nkx2-5 regulates Cardiac Growth Through Modulation of Wnt Signaling by R-spondin3,” Development (Cambridge, England) 141, no. 15 (2014): 2959–2971.

[164] S. Nallasamy, H. S. Kaya Okur, and A. Bhurke, “Msx Homeobox Genes Act Downstream of BMP2 to Regulate Endometrial Decidualization in Mice and in Humans,” Endocrinology 160, no. 7 (2019): 1631–1644.

[165] C. Xue, Q. Chu, Q. Shi, Y. Zeng, J. Lu, and L. Li, “Wnt Signaling Pathways in Biology and Disease: Mechanisms and Therapeutic Advances,” Signal Transduction and Targeted Therapy 10, no. 1 (2025): 106.

[166] B. T. Fenby, V. Fotaki, and J. O. Mason, “Pax3 regulates Wnt1 Expression via a Conserved Binding Site in the 5′ Proximal Promoter,” Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms 1779, no. 2 (2008): 115–121.

[167] X. Zeng, Y. Wang, Q. Dong, M.-X. Ma, and X.-D. Liu, “DLX2 activates Wnt1 Transcription and Mediates Wnt/β-catenin Signal to Promote Osteogenic Differentiation of hBMSCs,” Gene 744 (2020): 144564.

[168] B. Cha, X. Geng, M. R. Mahamud, et al., “Complementary Wnt Sources Regulate Lymphatic Vascular Development via PROX1-dependent Wnt/β-catenin Signaling,” Cell Reports 25, no. 3 (2018): 571–584. e5.

[169] L.-M. Pîrlog, A.-A. Pătrășcanu, M.-D. Ona, A. Cătană, and I. C. Rotar, “HOXA10 and HOXA11 in Human Endometrial Benign Disorders: Unraveling Molecular Pathways and Their Impact on Reproduction,” Biomolecules 15, no. 4 (2025): 563.

[170] J. Zeng, W. Sun, J. Chang, et al., “HOXC4 up-regulates NF-κB Signaling and Promotes the Cell Proliferation to Drive Development of human Hematopoiesis, Especially CD43+ Cells,” Blood Science 2, no. 04 (2020): 117–128.

[171] J. L. dos Santos Schiavinato, L. H. B. Oliveira, A. G. Araujo, et al., “TNF-alpha and Notch Signaling Regulates the Expression of HOXB4 and GATA3 During Early T Lymphopoiesis,” In Vitro Cellular & Developmental Biology-Animal 52, no. 9 (2016): 920–934.

[172] K. Yun, S. Fischman, J. Johnson, M. H. de Angelis, G. Weinmaster, and J. L. Rubenstein, “Modulation of the Notch Signaling by Mash1 and Dlx1/2 Regulates Sequential Specification and Differentiation of Progenitor Cell Types in the Subcortical Telencephalon,” Development (Cambridge, England) 129, no. 21 (2002): 5029–5040.

[173] Y. Zhang, Q. Huang, J.-C. Cheng, et al., “Homeobox A7 Increases Cell Proliferation by Up-regulation of Epidermal Growth Factor Receptor Expression in human Granulosa Cells,” Reproductive Biology and Endocrinology 8, no. 1 (2010): 61.

[174] Y. Suh, K. Obernier, G. Hölzl-Wenig, et al., “Interaction Between DLX2 and EGFR Regulates Proliferation and Neurogenesis of SVZ Precursors,” Molecular and Cellular Neuroscience 42, no. 4 (2009): 308–314.

[175] M. Vieux-Rochas, K. Bouhali, S. Mantero, et al., “BMP-mediated Functional Cooperation Between Dlx5; Dlx6 and Msx1; Msx2 During Mammalian Limb Development,” PLoS ONE 8, no. 1 (2013): e51700.

[176] J. S. Heo, S. G. Lee, and K. HO, “Distal-less Homeobox 5 Is a Master Regulator of the Osteogenesis of human Mesenchymal Stem Cells,” International Journal of Molecular Medicine 40, no. 5 (2017): 1486–1494.

[177] T. J. Cunningham and G. Duester, “Mechanisms of Retinoic Acid Signalling and Its Roles in Organ and Limb Development,” Nature reviews Molecular Cell Biology 16, no. 2 (2015): 110–123.

[178] L. Yin, F.-Y. Wang, W. Zhang, et al., “RA Signaling Pathway Combined With Wnt Signaling Pathway Regulates human-induced Pluripotent Stem Cells (hiPSCs) Differentiation to Sinus Node-Like Cells,” Stem Cell Research & Therapy 13, no. 1 (2022): 324.

[179] G. Su, D. Guo, J. Chen, et al., “A Distal Enhancer Maintaining Hoxa1 Expression Orchestrates Retinoic Acid-induced Early ESCs Differentiation,” Nucleic Acids Research 47, no. 13 (2019): 6737–6752.

[180] Y. Yang, X. Zhu, X. Jia, et al., “Phosphorylation of Msx1 Promotes Cell Proliferation Through the Fgf9/18-MAPK Signaling Pathway During Embryonic Limb Development,” Nucleic Acids Research 48, no. 20 (2020): 11452–11467.

[181] M. F. Ullo and L. B. Case, “How Cells Sense and Integrate Information From Different Sources,” WIREs Mechanisms of Disease 15, no. 4 (2023): e1604.

[182] P. N. Arya, I. Saranya, and N. Selvamurugan, “Crosstalk Between Wnt and Bone Morphogenetic Protein Signaling During Osteogenic Differentiation,” World Journal of Stem Cells 16, no. 2 (2024): 102.

[183] A. Wiesinger, G. J. Boink, V. M. Christoffels, and H. D. Devalla, “Retinoic Acid Signaling in Heart Development: Application in the Differentiation of Cardiovascular Lineages From human Pluripotent Stem Cells,” Stem Cell Reports 16, no. 11 (2021): 2589–2606.

[184] Y. Lee, J. Y. Lee, and M. H. Kim, “PI 3K/Akt Pathway Regulates Retinoic Acid-induced Hox Gene Expression in F9 Cells,” Development, Growth & Differentiation 56, no. 7 (2014): 518–525.

[185] N. Liu, N. Kawahira, Y. Nakashima, et al., “Notch and Retinoic Acid Signals Regulate Macrophage Formation From Endocardium Downstream of Nkx2-5,” Nature Communications 14, no. 1 (2023): 5398.

[186] K. A. Hubert and D. M. Wellik, “Hox Genes in Development and Beyond,” Development (Cambridge, England) 150, no. 1 (2023): dev192476.

[187] S. C. Quinonez and J. W. Innis, “Human HOX Gene Disorders,” Molecular Genetics and Metabolism 111, no. 1 (2014): 4–15.

[188] D. Wang, Y. Zhang, Q. Li, et al., “Epigenetics: Mechanisms, Potential Roles, and Therapeutic Strategies in Cancer Progression,” Genes & Diseases 11, no. 5 (2024): 101020.

[189] S. Samuel and H. Naora, “Homeobox Gene Expression in Cancer: Insights From Developmental Regulation and Deregulation,” European Journal of Cancer 41, no. 16 (2005): 2428–2437.

[190] M. Rodrigues, C. M. Esteves, F. C. A. Xavier, and F. D. Nunes, “Methylation Status of Homeobox Genes in Common human Cancers,” Genomics 108, no. 5-6 (2016): 185–193.

[191] R. Blanchett, K. H. Lau, and G. P. Pfeifer, “Homeobox and Polycomb Target Gene Methylation in human Solid Tumors,” Scientific Reports 14, no. 1 (2024): 13912.

[192] A. B. Weiner, F. A. Faisal, E. Davicioni, et al., “Somatic HOXB13 Expression Correlates With Metastatic Progression in Men With Localized Prostate Cancer Following Radical Prostatectomy,” European Urology Oncology 4, no. 6 (2021): 955–962.

[193] R. Karlsson, M. Aly, M. Clements, et al., “A Population-based Assessment of Germline HOXB13 G84E Mutation and Prostate Cancer Risk,” European Urology 65, no. 1 (2014): 169–176.

[194] M. R. Akbari, L. N. Anderson, D. D. Buchanan, et al., “Germline HOXB13 p. Gly84Glu Mutation and Risk of Colorectal Cancer,” Cancer Epidemiology 37, no. 4 (2013): 424–427.

[195] J. Wei, Z. Shi, R. Na, et al., “Germline HOXB13 G84E Mutation Carriers and Risk to Twenty Common Types of Cancer: Results From the UK Biobank,” British Journal of Cancer 123, no. 9 (2020): 1356–1359.

[196] A. Farsetti, B. Illi, and C. Gaetano, “How Epigenetics Impacts on human Diseases,” European Journal of Internal Medicine 114 (2023): 15–22.

[197] B. T. Yang, T. A. Dayeh, P. A. Volkov, et al., “Increased DNA Methylation and Decreased Expression of PDX-1 in Pancreatic Islets From Patients With Type 2 Diabetes,” Molecular Endocrinology 26, no. 7 (2012): 1203–1212.

[198] M. H. Elias, N. Lazim, Z. Sutaji, et al., “HOXA10 DNA Methylation Level in the Endometrium Women With Endometriosis: A Systematic Review,” Biology 12, no. 3 (2023): 474.

[199] M. Elias, N. Lazim, Z. Sutaji, M. Abu, and A. Abdul Karim, “HOXA10 DNA Methylation Level in the Endometrium Women With Endometriosis: A Systematic Review,” Biology (Basel) 12, no. 3 (2023): 474.

[200] O. Duverger and M. I. Morasso, “Role of Homeobox Genes in the Patterning, Specification, and Differentiation of Ectodermal Appendages in Mammals,” Journal of Cellular Physiology 216, no. 2 (2008): 337–346.

[201] D. H. Gorski and K. Walsh, “Control of Vascular Cell Differentiation by Homeobox Transcription Factors,” Trends in Cardiovascular Medicine 13, no. 6 (2003): 213–220.

[202] D. Lima Cunha, G. Arno, M. Corton, and M. Moosajee, “The Spectrum of PAX6 Mutations and Genotype-phenotype Correlations in the Eye,” Genes 10, no. 12 (2019): 1050.

[203] J. Hall, M. Corton, F. N. Fries, et al., “Comprehensive Analysis of Congenital Aniridia and Differential Diagnoses: Genetic Insights and Clinical Manifestations,” Ophthalmology and Therapy (2025): 1–22.

[204] E. Vitale, D. Ricci, F. Corrao, et al., “Nonsense Mutations in Rare and Ultra-Rare Human Disorders: An Overview,” Iubmb Life 77, no. 6 (2025): e70031.

[205] L. S. Nguyen, M. F. Wilkinson, and J. Gecz, “Nonsense-mediated mRNA Decay: Inter-individual Variability and human Disease,” Neuroscience & Biobehavioral Reviews 46 (2014): 175–186.

[206] N. Si, X. Meng, X. Lu, et al., “Identification of Loss-of-function HOXA2 Mutations in Chinese Families With Dominant Bilateral Microtia,” Gene 757 (2020): 144945.

[207] Y. Zheng, C. Sun, X. Zhang, P. A. Ruzycki, and S. Chen, “Missense Mutations in CRX Homeodomain Cause Dominant Retinopathies Through Two Distinct Mechanisms,” Elife 12 (2023): RP87147.

[208] I. Dorboz, C. Aiello, C. Simons, et al., “Biallelic Mutations in the Homeodomain of NKX6-2 Underlie a Severe Hypomyelinating Leukodystrophy,” Brain 140, no. 10 (2017): 2550–2556.

[209] A. Murtazina, A. Borovikov, A. Kuchina, et al., “Expanding the Phenotype of Hereditary Congenital Facial Paresis Type 3,” International Journal of Molecular Sciences 25, no. 1 (2023): 129.

[210] M. Pelleter, C. Desaintjean, R. Gyapay, et al., “A New Nonsense Pathogenic Variant in Exon 1 of PHOX2B Leads to the Diagnosis of Congenital central Hypoventilation Syndrome With Intra-familial Variability,” Archives de Pédiatrie 31, no. 7 (2024): 470–472.

[211] A. Sezer, F. E. Perçin, H. H. Kazan, G. Kayhan, and M. Akturk, “A De Novo Heterozygous HOXA11 Variant in a Patient With Mesomelic Dysplasia With Urogenital Abnormalities,” American Journal of Medical Genetics Part A 188, no. 6 (2022): 1890–1895.

[212] L. Cao, C. Chen, Y. Leng, et al., “A Missense Mutation of HOXA13 Underlies Hand-foot-genital Syndrome in a Chinese family,” Journal of Genetics 96, no. 4 (2017): 647–652.

[213] L. Zhang, Z. Fang, G. Cheng, M. He, and Y. Lin, “A Novel Hoxd13 Mutation Causes Synpolydactyly and Promotes Osteoclast Differentiation by Regulating pSmad5/p65/c-Fos/Rank Axis,” Cell Death & Disease 14, no. 2 (2023): 145.

[214] V. Barca-Tierno, M. Aza-Carmona, E. Barroso, et al., “Identification of a Gypsy SHOX Mutation (p. A170P) in Léri-Weill Dyschondrosteosis and Langer Mesomelic Dysplasia,” European Journal of Human Genetics 19, no. 12 (2011): 1218–1225.

[215] E. Klopocki, C. Kähler, N. Foulds, et al., “Deletions in PITX1 Cause a Spectrum of Lower-limb Malformations Including Mirror-image Polydactyly,” European Journal of Human Genetics 20, no. 6 (2012): 705–708.

[216] X. Wang, Q. Xin, L. Li, et al., “Exome Sequencing Reveals a Heterozygous DLX5 Mutation in a Chinese family With Autosomal-dominant Split-hand/Foot Malformation,” European Journal of Human Genetics 22, no. 9 (2014): 1105–1110.

[217] R. S. Tooze, K. A. Miller, S. M. Swagemakers, et al., “Pathogenic Variants in the Paired-related Homeobox 1 Gene (PRRX1) Cause Craniosynostosis With Incomplete Penetrance,” Genetics in Medicine 25, no. 9 (2023): 100883.

[218] J. Adachi, Y. Aoki, T. Tatematsu, et al., “Novel MSX1 Frameshift Mutation in a Japanese family With Nonsyndromic Oligodontia,” Human Genome Variation 8, no. 1 (2021): 29.

[219] J. M. Florisson, A. J. Verkerk, D. Huigh, et al., “Boston Type Craniosynostosis: Report of a Second Mutation in MSX2,” American Journal of Medical Genetics Part A 161, no. 10 (2013): 2626–2633.

[220] N. Intarak, K. Tongchairati, K. Termteerapornpimol, S. Chantarangsu, and T. Porntaveetus, “Tooth Agenesis Patterns and Variants in PAX9: A Systematic Review,” Japanese Dental Science Review 59 (2023): 129–137.

[221] J. Quan, Y. Liu, L. Ji, Y. Zhao, and S. Zheng, “A Novel DLX3 Mutation Causes Tricho-dento-osseous Syndrome With Abnormal Enamel Structure and Formation,” Archives of Oral Biology 157 (2024): 105849.

[222] H. Kayserili, E. Uz, C. Niessen, et al., “ALX4 dysfunction Disrupts Craniofacial and Epidermal Development,” Human Molecular Genetics 18, no. 22 (2009): 4357–4366.

[223] R. Guo, X. Zhang, A. Liu, J. Ji, and W. Liu, “Novel Clinical Presentation and PAX6 Mutation in Families With Congenital Aniridia,” Frontiers in Medicine 9 (2022): 1042588.

[224] S. Wangding, S. Colaiacovo, I. Makar, and M. Saleh, “OTX2 mutation Associated With Severe Myopia in a Canadian family,” Ophthalmic Genetics 43, no. 3 (2022): 389–391.

[225] L. M. Reis, A. Khan, A. Kariminejad, F. Ebadi, R. C. Tyler, and E. V. Semina, “VSX2 mutations in Autosomal Recessive Microphthalmia,” Molecular Vision 17 (2011): 2527.

[226] L. Zhou, Z. Xu, Q. Wu, and X. Wei, “Unilateral Buphthalmos, Corneal Staphyloma and Corneal Fistula Caused by Pathogenic Variant in the PITX3 Gene: A Case Report,” BMC Ophthalmology 22, no. 1 (2022): 385.

[227] I. Schrauwen, I. Chakchouk, K. Liaqat, et al., “A Variant in LMX1A Causes Autosomal Recessive Severe-to-profound Hearing Impairment,” Human Genetics 137, no. 6 (2018): 471–478.

[228] N. Camats, N. Baz-Redón, M. Fernández-Cancio, et al., “Phenotypic Variability of Patients With PAX8 Variants Presenting With Congenital Hypothyroidism and Eutopic Thyroid,” The Journal of Clinical Endocrinology & Metabolism 106, no. 1 (2021): e152–e170.

[229] S. A. Vishnopolska, M. F. Mercogliano, M. A. Camilletti, et al., “Comprehensive Identification of Pathogenic Gene Variants in Patients With Neuroendocrine Disorders,” The Journal of Clinical Endocrinology & Metabolism 106, no. 7 (2021): 1956–1976.

[230] E. Coutinho, C. M. Brandão, and M. C. Lemos, “Combined Pituitary Hormone Deficiency Caused by a Synonymous HESX1 Gene Mutation,” The Journal of Clinical Endocrinology & Metabolism 104, no. 7 (2019): 2851–2854.

[231] B. Haris, I. Mohammed, N. Syed, K. Fakhro, and K. Hussain, “Maturity-onset Diabetes of the Young (MODY) due to PDX1 Mutation in a Sib-pair Diabetes family From Qatar,” Clinical Case Reports 9, no. 12 (2021): e05141.

[232] D. Zhang, C. Chen, W. Yang, Y. Piao, L. Ren, and Y. C. Sang, “487C>T Mutation in PAX4 Gene Causes MODY9: A Case Report and Literature Review,” Medicine 101, no. 51 (2022): e32461.

[233] P. Morlanes-Gracia, G. Antoniutti, J. Alvarez-Rubio, L. Torres-Juan, D. Heine-Suñer, and T. Ripoll-Vera, “Case Report: A Novel NKX2-5 Mutation in a family With Congenital Heart Defects, Left Ventricular Non-compaction, Conduction Disease, and Sudden Cardiac Death,” Frontiers in Cardiovascular Medicine 8 (2021): 691203.

[234] A. Herraiz-Martínez, C. Tarifa, E. Lozano-Velasco, et al., “Novel PITX2 Homeodomain-contained Mutations From ATRIAL Fibrillation Patients Deteriorate Calcium Homeostasis,” Hearts 2, no. 2 (2021): 251–269.

[235] S. Hoffmann, C. Paone, S. A. Sumer, et al., “Functional Characterization of Rare Variants in the SHOX2 Gene Identified in Sinus Node Dysfunction and Atrial Fibrillation,” Frontiers in Genetics 10 (2019): 648.

[236] W. Yao, B. Xu, H. Wang, et al., “A Novel Synonymous Variant of PAX2 in Monochorionic Diamniotic Twins with Bilateral Renal Agenesis: A Case Report and Literature Review,” Molecular Genetics & Genomic Medicine 13, no. 6 (2025): e70113.

[237] F. Petzold, W. Jin, E. Hantmann, K. Korbach, R. Schönauer, and J. Halbritter, “Novel Somatic PBX1 Mosaicism Likely Masking Syndromic CAKUT in an Adult With Bilateral Kidney Hypoplasia,” Clinical Kidney Journal 15, no. 7 (2022): 1333–1339.

[238] Y. Zhu, Z. Cheng, J. Wang, et al., “A Novel Mutation of HOXA11 in a Patient With Septate Uterus,” Orphanet Journal of Rare Diseases 12, no. 1 (2017): 178.

[239] W. Zhang, X. Zhou, L. Liu, et al., “Identification and Functional Analysis of a Novel LHX1 Mutation Associated With Congenital Absence of the Uterus and Vagina,” Oncotarget 8, no. 5 (2017): 8785.

[240] P. Jordan, C. Verebi, S. Perol, et al., “NOBOX Gene Variants in Premature Ovarian Insufficiency: Ethnicity-dependent Insights,” Journal of Assisted Reproduction and Genetics 41, no. 1 (2024): 135–146.

[241] E. F. Evans, Z. A. Shyr, B. J. Traynor, and W. Zheng, “Therapeutic Development Approaches to Treat Haploinsufficiency Diseases: Restoring Protein Levels,” Drug Discovery Today 29, no. 12 (2024): 104201.

[242] L. C. Gregory, P. Gergics, M. Nakaguma, et al., “The Phenotypic Spectrum Associated With OTX2 Mutations in Humans,” European Journal of Endocrinology 185, no. 1 (2021): 121–135.

[243] M. Fukami, A. Seki, and T. Ogata, “SHOX Haploinsufficiency as a Cause of Syndromic and Nonsyndromic Short Stature,” Molecular Syndromology 7, no. 1 (2016): 3–11.

[244] E. C. Landsend, N. Lagali, and T. P. Utheim, “Congenital aniridia–A Comprehensive Review of Clinical Features and Therapeutic Approaches,” Survey of Ophthalmology 66, no. 6 (2021): 1031–1050.

[245] Y. Jiang, S. Li, X. Xiao, W. Sun, and Q. Zhang, “Genotype-phenotype of Isolated Foveal Hypoplasia in a Large Cohort: Minor Iris Changes as an Indicator of PAX6 Involvement,” Investigative Ophthalmology & Visual Science 62, no. 10 (2021): 23–23.

[246] D. Lima Cunha, N. Owen, V. Tailor, M. Corton, M. Theodorou, and M. Moosajee, “PAX6 missense Variants in Two Families With Isolated Foveal Hypoplasia and Nystagmus: Evidence of Paternal Postzygotic Mosaicism,” European Journal of Human Genetics 29, no. 2 (2021): 349–355.

[247] T. Yokoi, S. Nishina, M. Fukami, et al., “Genotype–phenotype Correlation of PAX6 Gene Mutations in Aniridia,” Human Genome Variation 3, no. 1 (2016): 1–5.

[248] R. Guo, X. Fang, H. Mao, et al., “A Novel Missense Variant of HOXD13 Caused atypical Synpolydactyly by Impairing the Downstream Gene Expression and Literature Review for Genotype–phenotype Correlations,” Frontiers in Genetics 12 (2021): 731278.

[249] A. Zhou, C. M. Rand, S. M. Hockney, et al., “Paired-Like Homeobox Gene (PHOX2B) Nonpolyalanine Repeat Expansion Mutations (NPARMs): Genotype–phenotype Correlation in Congenital central Hypoventilation Syndrome (CCHS),” Genetics in Medicine 23, no. 9 (2021): 1656–1663.

[250] D. Kudlay, V. Kiselev, and G. Sukhikh, “HOXA10 and HOXA11 Methylation: Epigenetic Barriers to Endometrial Receptivity in ART,” Genes 16, no. 10 (2025): 1230.

[251] X. Li, T.-K. Ma, P. Wang, et al., “HOXD10 attenuates Renal Fibrosis by Inhibiting NOX4-induced Ferroptosis,” Cell Death & Disease 15, no. 6 (2024): 398.

[252] X. Xiao, W. Wang, C. Guo, et al., “Hypermethylation Leads to the Loss of HOXA5, Resulting in JAG1 Expression and NOTCH Signaling Contributing to Kidney Fibrosis,” Kidney International 106, no. 1 (2024): 98–114.

[253] W. Feng, H. Destain, J. J. Smith, and P. Kratsios, “Maintenance of Neurotransmitter Identity by Hox Proteins Through a Homeostatic Mechanism,” Nature Communications 13, no. 1 (2022): 6097.

[254] V. B. Fedoseyeva, E. V. Novosadova, V. V. Nenasheva, L. V. Novosadova, I. A. Grivennikov, and V. Z. Tarantul, “Transcription of HOX Genes Is Significantly Increased During Neuronal Differentiation of iPSCs Derived From Patients With Parkinson's Disease,” Journal of Developmental Biology 11, no. 2 (2023): 23.

[255] H. Doucet-Beaupré, C. Gilbert, M. S. Profes, et al., “Lmx1a and Lmx1b Regulate Mitochondrial Functions and Survival of Adult Midbrain Dopaminergic Neurons,” Proceedings of the National Academy of Sciences of the United States of AMerica 113, no. 30 (2016): E4387–E4396.

[256] J. A. Roubroeks, A. R. Smith, R. G. Smith, et al., “An Epigenome-wide Association Study of Alzheimer's disease Blood Highlights Robust DNA Hypermethylation in the HOXB6 Gene,” Neurobiology of Aging 95 (2020): 26–45.

[257] Y. Zhang, Y. Zhang, Y. Aman, et al., “Amyloid-β Toxicity Modulates Tau Phosphorylation Through the PAX6 Signalling Pathway,” Brain 144, no. 9 (2021): 2759–2770.

[258] R. G. Smith, E. Hannon, and P. L. De Jager, “Elevated DNA Methylation Across a 48-kb Region Spanning the HOXA Gene Cluster Is Associated With Alzheimer's Disease Neuropathology,” Alzheimer's & Dementia 14, no. 12 (2018): 1580–1588.

[259] Z. Wu, H. Guo, N. Chow, et al., “Role of the MEOX2 Homeobox Gene in Neurovascular Dysfunction in Alzheimer Disease,” Nature Medicine 11, no. 9 (2005): 959–965.

[260] Y. Wang, X. Chen, Y. Wang, S. Li, H. Cai, and W. Le, “The Essential Role of Transcription Factor Pitx3 in Preventing Mesodiencephalic Dopaminergic Neurodegeneration and Maintaining Neuronal Subtype Identities During Aging,” Cell Death & Disease 12, no. 11 (2021): 1008.

[261] H. Liu, L. Wei, Q. Tao, et al., “Decreased NURR1 and PITX3 Gene Expression in Chinese Patients With Parkinson's Disease,” European Journal of Neurology 19, no. 6 (2012): 870–875.

[262] J. C. Villaescusa, B. Li, E. M. Toledo, et al., “A PBX1 Transcriptional Network Controls Dopaminergic Neuron Development and Is Impaired in Parkinson's Disease,” The EMBO Journal 35, no. 18 (2016): 1963–1978.

[263] A. Verma, R. P. Kommaddi, B. Gnanabharathi, E. C. Hirsch, and V. Ravindranath, “Genes Critical for Development and Differentiation of Dopaminergic Neurons Are Downregulated in Parkinson's disease,” Journal of Neural Transmission 130, no. 4 (2023): 495–512.

[264] A. Laguna, N. Schintu, A. Nobre, et al., “Dopaminergic Control of Autophagic-lysosomal Function Implicates Lmx1b in Parkinson's Disease,” Nature Neuroscience 18, no. 6 (2015): 826–835.

[265] H. Sim, J.-E. Lee, H. M. Yoo, et al., “Iroquois Homeobox Protein 2 Identified as a Potential Biomarker for Parkinson's Disease,” International Journal of Molecular Sciences 21, no. 10 (2020): 3455.

[266] H. Kurniawan, S. L. Nickels, A. Zagare, et al., “The Parkinson's Disease-associated LRRK2-G2019S Variant Restricts Serine Metabolism, Leading to Microglial Inflammation and Dopaminergic Neuron Degeneration,” Journal of Neuroinflammation 22, no. 1 (2025): 1–17.

[267] S. Mitsuzawa, N. Suzuki, T. Akiyama, et al., “Reduced PHOX2B Stability Causes Axonal Growth Impairment in Motor Neurons With TARDBP Mutations,” Stem Cell Reports 16, no. 6 (2021): 1527–1541.

[268] N. A. Finch, X. Wang, M. C. Baker, et al., “Abnormal Expression of Homeobox Genes and Transthyretin in C9ORF72 Expansion Carriers,” Neurology: Genetics 3, no. 4 (2017): e161.

[269] Y. Qian, G. Arellano, I. Ifergan, et al., “ZEB1 promotes Pathogenic Th1 and Th17 Cell Differentiation in Multiple Sclerosis,” Cell Reports 36, no. 8 (2021): 109602.

[270] A. G. Hoss, V. K. Kartha, X. Dong, et al., “MicroRNAs Located in the Hox Gene Clusters Are Implicated in Huntington's Disease Pathogenesis,” PLoS Genetics 10, no. 2 (2014): e1004188.

[271] T. Celià-Terrassa and Y. Kang, “How Important Is EMT for Cancer Metastasis?,” PLoS Biology 22, no. 2 (2024): e3002487.

[272] A. Francou and K. V. Anderson, “The Epithelial-to-mesenchymal Transition in Development and Cancer,” Annual Review of Cancer Biology 4, no. 1 (2020): 197–220.

[273] S. Lin, R. Zhang, X. An, et al., “LncRNA HOXA-AS3 Confers Cisplatin Resistance by Interacting With HOXA3 in Non-small-cell Lung Carcinoma Cells,” Oncogenesis 8, no. 11 (2019): 60.

[274] V. Kumar, M. Vashishta, L. Kong, et al., “The Role of Notch, Hedgehog, and Wnt Signaling Pathways in the Resistance of Tumors to Anticancer Therapies,” Frontiers in Cell and Developmental Biology 9 (2021): 650772.

[275] M. K. Joo, J.-J. Park, and H. J. Chun, “Impact of Homeobox Genes in Gastrointestinal Cancer,” World Journal of Gastroenterology 22, no. 37 (2016): 8247.

[276] L. He, M. Liang, W. Guo, J. Liu, and Y. Yu, “HOXA1 is a Radioresistance Marker in Multiple Cancer Types,” Frontiers in Oncology 12 (2022): 965427.

[277] K. Lee, J. W. Chang, C. Oh, et al., “HOXB5 acts as an Oncogenic Driver in Head and Neck Squamous Cell Carcinoma via EGFR/Akt/Wnt/β-catenin Signaling Axis,” European Journal of Surgical Oncology 46, no. 6 (2020): 1066–1073.

[278] X. Wu, J. Li, T. Yan, et al., “HOXB7 acts as an Oncogenic Biomarker in Head and Neck Squamous Cell Carcinoma,” Cancer Cell International 21, no. 1 (2021): 393.

[279] L. Wang, J. Jin, and Y. Zhou, “EMX2 is Epigenetically Silenced and Suppresses Epithelial‑Mesenchymal Transition in human Esophageal Adenocarcinoma,” Oncology Reports 42, no. 5 (2019): 2169–2178.

[280] T. Otsubo, K. Yamada, T. Hagiwara, et al., “DNA Hypermethyation and Silencing of PITX1 Correlated With Advanced Stage and Poor Postoperative Prognosis of Esophageal Squamous Cell Carcinoma,” Oncotarget 8, no. 48 (2017): 84434.

[281] U. S. Shenoy, D. S. Basavarajappa, S. P. Kabekkodu, and R. Radhakrishnan, “Pan-cancer Exploration of Oncogenic and Clinical Impacts Revealed That HOXA9 Is a Diagnostic Indicator of Tumorigenesis,” Clinical and Experimental Medicine 24, no. 1 (2024): 134.

[282] S. Aryal, Y. Zhang, S. Wren, C. Li, and R. Lu, “Molecular Regulators of HOXA9 in Acute Myeloid Leukemia,” The FEBS Journal 290, no. 2 (2023): 321–339.

[283] L. Tang, L. Peng, C. Tan, H. Liu, P. Chen, and H. Wang, “Role of HOXA9 in Solid Tumors: Mechanistic Insights and Therapeutic Potential,” Cancer Cell International 22, no. 1 (2022): 349.

[284] A. Budreika, J. T. Phoenix, R. J. Kostlan, et al., “The Homeobox Transcription Factor NKX3. 1 Displays an Oncogenic Role in Castration-Resistant Prostate Cancer Cells,” Cancers 17, no. 2 (2025): 306.

[285] B. Arneth, “Tumor Microenvironment,” Medicina 56, no. 1 (2019): 15.

[286] J. M. Northcott, J. J. Northey, J. M. Barnes, and V. M. Weaver, “Fighting the Force: Potential of Homeobox Genes for Tumor Microenvironment Regulation,” Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1855, no. 2 (2015): 248–253.

[287] T. Steinbichler, D. Savic, D. Dejaco, et al., “Pleiotropic Effects of Epithelial Mesenchymal Crosstalk on Head and Neck Cancer: EMT and Beyond,” Cancer Microenvironment 12, no. 2 (2019): 67–76.

[288] X. He, B. Lee, and Y. Jiang, “Extracellular Matrix in Cancer Progression and Therapy,” Medical Review 2, no. 2 (2022): 125–139.

[289] J. Sarrand and M. S. Soyfoo, “Involvement of Epithelial-mesenchymal Transition (EMT) in Autoimmune Diseases,” International Journal of Molecular Sciences 24, no. 19 (2023): 14481.

[290] M. Liaghat, S. Ferdousmakan, S. H. Mortazavi, et al., “The Impact of Epithelial-mesenchymal Transition (EMT) Induced by Metabolic Processes and Intracellular Signaling Pathways on Chemo-resistance, Metastasis, and Recurrence in Solid Tumors,” Cell Communication and Signaling 22, no. 1 (2024): 1–24.

[291] N. Mukerjee, S. Nag, B. Bhattacharya, et al., “Clinical Impact of Epithelial–mesenchymal Transition for Cancer Therapy,” Clinical and Translational Discovery 4, no. 1 (2024): e260.

[292] X. Zhu, L. Wei, Y. Bai, S. Wu, and S. Han, “FoxC1 promotes Epithelial-mesenchymal Transition Through PBX1 Dependent Transactivation of ZEB2 in Esophageal Cancer,” American Journal of Cancer Research 7, no. 8 (2017): 1642.

[293] U. S. Shenoy, D. Adiga, S. Gadicherla, S. P. Kabekkodu, K. D. Hunter, and R. Radhakrishnan, “HOX Cluster-embedded lncRNAs and Epithelial-mesenchymal Transition in Cancer: Molecular Mechanisms and Therapeutic Opportunities,” Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1878, no. 1 (2023): 188840.

[294] M. Roux and S. Zaffran, “Hox Genes in Cardiovascular Development and Diseases,” Journal of Developmental Biology 4, no. 2 (2016): 14.

[295] D. H. Gorski and K. Walsh, “The Role of Homeobox Genes in Vascular Remodeling and Angiogenesis,” Circulation Research 87, no. 10 (2000): 865–872.

[296] P. Murthi, M. Abumaree, and B. Kalionis, “Analysis of Homeobox Gene Action May Reveal Novel Angiogenic Pathways in Normal Placental Vasculature and in Clinical Pregnancy Disorders Associated With Abnormal Placental Angiogenesis,” Frontiers in Pharmacology 5 (2014): 133.

[297] A. Pathak, A. K. Pal, S. Roy, M. Nandave, and K. Jain, “Role of Angiogenesis and Its Biomarkers in Development of Targeted Tumor Therapies,” Stem Cells International 2024, no. 1 (2024): 9077926.

[298] U. S. Shenoy, D. Adiga, F. Alhedyan, S. P. Kabekkodu, and R. Radhakrishnan, “HOXA9 transcription Factor Is a Double-edged Sword: From Development to Cancer Progression,” Cancer and Metastasis Reviews 43, no. 2 (2024): 709–728.

[299] Z.-L. Liu, H.-H. Chen, L.-L. Zheng, L.-P. Sun, and L. Shi, “Angiogenic Signaling Pathways and Anti-angiogenic Therapy for Cancer,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 198.

[300] A. Ullah, A. Razzaq, C. Zhou, et al., “Biological Significance of EphB4 Expression in Cancer,” Current Protein and Peptide Science 25, no. 3 (2024): 244–255.

[301] S. Ramazi, M. Dadzadi, Z. Sahafnejad, and A. Allahverdi, “Epigenetic Regulation in Lung Cancer,” MedComm 4, no. 6 (2023): e401.

[302] S. Ramazi, M. Dadzadi, M. Darvazi, N. Seddigh, and A. Allahverdi, “Protein Modification in Neurodegenerative Diseases,” MedComm 5, no. 8 (2024): e674.

[303] A. Paço, S. A. de Bessa Garcia, and R. Freitas, “Methylation in HOX Clusters and Its Applications in Cancer Therapy,” Cells 9, no. 7 (2020): 1613.

[304] S. Ramazi and J. Zahiri, “Post-translational Modifications in Proteins: Resources, Tools and Prediction Methods,” Database 2021 (2021): baab012.

[305] S. Ramazi, A. Allahverdi, and J. Zahiri, “Evaluation of Post-translational Modifications in Histone Proteins: A Review on Histone Modification Defects in Developmental and Neurological Disorders,” Journal of Biosciences 45, no. 1 (2020): 135.

[306] S. Ramazi, M. Dadzadi, Z. Sahafnejad, and A. Allahverdi, “Histone Modification and Personalized Epigenomics in cancer,” Personalized Epigenetics. (Elsevier, 2024): 429–473.

[307] Q. Wang, F. Xiong, G. Wu, et al., “Gene Body Methylation in Cancer: Molecular Mechanisms and Clinical Applications,” Clinical Epigenetics 14, no. 1 (2022): 154.

[308] F. Yang, D. Liu, Y. Deng, et al., “Frequent Promoter Methylation of HOXD10 in Endometrial Carcinoma and Its Pathological Significance,” Oncology Letters 19, no. 5 (2020): 3602–3608.

[309] F. Fan, H. Mo, H. Zhang, et al., “HOXA5: A Crucial Transcriptional Factor in Cancer and a Potential Therapeutic Target,” Biomedicine & Pharmacotherapy 155 (2022): 113800.

[310] M. H. Elias, H. Azlan, S. Sulong, A. A. Baba, and R. Ankathil, “Aberrant DNA Methylation at HOXA4 and HOXA5 Genes Are Associated With Resistance to Imatinib Mesylate Among Chronic Myeloid Leukemia Patients,” Cancer Reports 1, no. 2 (2018): e1111.

[311] Z. Zhong, M. Shan, J. Wang, et al., “HOXD13 methylation Status Is a Prognostic Indicator in Breast Cancer,” International Journal of Clinical and Experimental Pathology 8, no. 9 (2015): 10716.

[312] J. Kim, D.-H. Bae, J. H. Kim, K.-S. Song, Y. S. Kim, and S.-Y. Kim, “HOXC10 overexpression Promotes Cell Proliferation and Migration in Gastric Cancer,” Oncology Reports 42, no. 1 (2019): 202–212.

[313] M. Li, J. S. Alsager, Z. Wang, L. Cheng, and B. Shan, “Epigenetic Upregulation of HOXC10 in Non-small Lung Cancer Cells,” Aging (Albany NY) 12, no. 17 (2020): 16921.

[314] J. Su, Y.-H. Huang, X. Cui, et al., “Homeobox Oncogene Activation by Pan-cancer DNA Hypermethylation,” Genome Biology 19 (2018): 1–12.

[315] V. Aliperti, J. Skonieczna, and A. Cerase, “Long Non-coding RNA (lncRNA) Roles in Cell Biology, Neurodevelopment and Neurological Disorders,” Non-Coding RNA 7, no. 2 (2021): 36.

[316] M. Chetta, L. Di Pietro, N. Bukvic, and W. Lattanzi, “Rising Roles of Small Noncoding RNAs in Cotranscriptional Regulation: In Silico Study of miRNA and piRNA Regulatory Network in Humans,” Genes 11, no. 5 (2020): 482.

[317] S. Yekta, C. J. Tabin, and D. P. Bartel, “MicroRNAs in the Hox Network: An Apparent Link to Posterior Prevalence,” Nature Reviews Genetics 9, no. 10 (2008): 789–796.

[318] L. D. Nguyen, Z. Wei, M. C. Silva, et al., “Small Molecule Regulators of microRNAs Identified by High-throughput Screen Coupled With High-throughput Sequencing,” Nature Communications 14, no. 1 (2023): 7575.

[319] X. Shi, L. Zhan, C. Xiao, et al., “miR-1238 Inhibits Cell Proliferation by Targeting LHX2 in Non-small Cell Lung Cancer,” Oncotarget 6, no. 22 (2015): 19043.

[320] L. Men, D. Nie, and H. Nie, “microRNA‑577 Inhibits Cell Proliferation and Invasion in Non‑Small Cell Lung Cancer by Directly Targeting Homeobox A1,” Molecular Medicine Reports 19, no. 3 (2019): 1875–1882.

[321] L. Boldrini, M. Giordano, G. Alì, et al., “P2×7 mRNA Expression in Non‑Small Cell Lung Cancer: MicroRNA Regulation and Prognostic Value,” Oncology Letters 9, no. 1 (2015): 449–453.

[322] Y. Wang, Y. Dang, J. Liu, and X. Ouyang, “The Function of Homeobox Genes and lncRNAs in Cancer,” Oncology Letters 12, no. 3 (2016): 1635–1641.

[323] L. Statello, C.-J. Guo, L.-L. Chen, and M. Huarte, “Gene Regulation by Long Non-coding RNAs and Its Biological Functions,” Nature Reviews Molecular Cell Biology 22, no. 2 (2021): 96–118.

[324] X. Zhang, W. Wang, W. Zhu, et al., “Mechanisms and Functions of Long Non-coding RNAs at Multiple Regulatory Levels,” International Journal of Molecular Sciences 20, no. 22 (2019): 5573.

[325] H. Tao, J.-J. Yang, X. Zhou, Z.-Y. Deng, K.-H. Shi, and J. Li, “Emerging Role of Long Noncoding RNAs in Lung Cancer: Current Status and Future Prospects,” Respiratory Medicine 110 (2016): 12–19.

[326] M. Yang, X. Hu, B. Tang, and F. Deng, “Exploring the Interplay Between Methylation Patterns and Non-coding RNAs in Non-small Cell Lung Cancer: Implications for Pathogenesis and Therapeutic Targets,” Heliyon 10, no. 2 (2024): e24811.

[327] K. Yang, H. Liu, and J. H. Li, “A Methylation-related lncRNA-based Prediction Model in Lung Adenocarcinomas,” The Clinical Respiratory Journal 18, no. 8 (2024): e13753.

[328] L. Shao, Z. Chen, D. Peng, et al., “Methylation of the HOXA10 Promoter Directs miR-196b-5p–dependent Cell Proliferation and Invasion of Gastric Cancer Cells,” Molecular Cancer Research 16, no. 4 (2018): 696–706.

[329] J. Gencel-Augusto, W. Wu, and T. G. Bivona, “Long Non-coding RNAs as Emerging Targets in Lung Cancer,” Cancers 15, no. 12 (2023): 3135.

[330] Q. Hu, H. Ma, H. Chen, Z. Zhang, and Q. Xue, “LncRNA in Tumorigenesis of Non-small-cell Lung Cancer: From Bench to Bedside,” Cell Death Discovery 8, no. 1 (2022): 359.

[331] G.-E. Lai, J. Zhou, C.-L. Huang, et al., “A Combination of Transcriptome and Methylation Analyses Reveals the Role of lncRNA HOTAIRM1 in the Proliferation and Metastasis of Breast Cancer,” Gland Surgery 11, no. 5 (2022): 826.

[332] A. Sharma, R. Mir, and S. Galande, “Epigenetic Regulation of the Wnt/β-catenin Signaling Pathway in Cancer,” Frontiers in Genetics 12 (2021): 681053.

[333] J. Rapp, L. Jaromi, K. Kvell, G. Miskei, and J. E. Pongracz, “WNT Signaling–lung Cancer Is no Exception,” Respiratory Research 18 (2017): 1–16.

[334] A. S. Hancock, C. J. Stairiker, A. C. Boesteanu, et al., “Transcriptome Analysis of Infected and Bystander Type 2 Alveolar Epithelial Cells During influenza A Virus Infection Reveals in Vivo Wnt Pathway Downregulation,” Journal of Virology 92, no. 21 (2018). e01325-18.

[335] C. Shi, T. Lv, Z. Xiang, Z. Sun, W. Qian, and X. Han, “Role of Wnt/β-Catenin Signaling in Epithelial Differentiation of Lung Resident Mesenchymal Stem Cells,” Journal of Cellular Biochemistry 116, no. 8 (2015): 1532–1539.

[336] C. J. Aros, C. J. Pantoja, and B. N. Gomperts, “Wnt Signaling in Lung Development, Regeneration, and Disease Progression,” Communications Biology 4, no. 1 (2021): 601.

[337] S. Muto, A. Enta, Y. Maruya, et al., “Wnt/β-catenin Signaling and Resistance to Immune Checkpoint Inhibitors: From Non-small-cell Lung Cancer to Other Cancers,” Biomedicines 11, no. 1 (2023): 190.

[338] A. A. Raslan and J. K. Yoon, “WNT Signaling in Lung Repair and Regeneration,” Molecules and Cells 43, no. 9 (2020): 774–783.

[339] H. Zhao, T. Ming, S. Tang, et al., “Wnt Signaling in Colorectal Cancer: Pathogenic Role and Therapeutic Target,” Molecular Cancer 21, no. 1 (2022): 144.

[340] Y.-J. Li, Z.-M. Wei, Y.-X. Meng, and X.-R. Ji, “β-catenin Up-regulates the Expression of cyclinD1, c-myc and MMP-7 in human Pancreatic Cancer: Relationships With Carcinogenesis and Metastasis,” World journal of Gastroenterology: WJG 11, no. 14 (2005): 2117.

[341] S. Qie and J. A. Diehl, “Cyclin D1, Cancer Progression, and Opportunities in Cancer Treatment,” Journal of Molecular Medicine 94 (2016): 1313–1326.

[342] F. Montalto and F. De Amicis, “Cyclin D1 in Cancer: A Molecular Connection for Cell Cycle Control, Adhesion and Invasion in Tumor and Stroma,” Cells 9 (2020): 2648.

[343] N. J. Wallbillich and H. Lu, “Role of c-Myc in Lung Cancer: Progress, Challenges, and Prospects,” Chinese Medical Journal Pulmonary and Critical Care Medicine 1, no. 03 (2023): 129–138.

[344] P. Chanvorachote, N. Sriratanasak, and N. Nonpanya, “C-myc Contributes to Malignancy of Lung Cancer: A Potential Anticancer Drug Target,” Anticancer Research 40, no. 2 (2020): 609–618.

[345] C. T. Harrington, E. Sotillo, C. V. Dang, and A. Thomas-Tikhonenko, “Tilting MYC Toward Cancer Cell Death,” Trends in Cancer 7, no. 11 (2021): 982–994.

[346] M. Dragoj, J. Bankovic, A. Podolski-Renic, et al., “Association of Overexpressed MYC Gene With Altered PHACTR3 and E2F4 Genes Contributes to Non-small Cell Lung Carcinoma Pathogenesis,” Journal of Medical Biochemistry 38, no. 2 (2019): 188.

[347] D. J. Stewart, “Wnt Signaling Pathway in Non–small Cell Lung Cancer,” Journal of the National Cancer Institute 106, no. 1 (2014): djt356.

[348] B. Zhang, N. Li, and H. Zhang, “Knockdown of Homeobox B5 (HOXB5) Inhibits Cell Proliferation, Migration, and Invasion in Non-small Cell Lung Cancer Cells Through Inactivation of the Wnt/β-catenin Pathway,” Oncology Research 26, no. 1 (2018): 37.

[349] S. Cheng, F. Qian, Q. Huang, L. Wei, Y. Fu, and Y. Du, “HOXA4, Down-regulated in Lung Cancer, Inhibits the Growth, Motility and Invasion of Lung Cancer Cells,” Cell Death & Disease 9, no. 5 (2018): 465.

[350] D. Lei, W.-T. Yang, and P.-S. Zheng, “HOXB4 inhibits the Proliferation and Tumorigenesis of Cervical Cancer Cells by Downregulating the Activity of Wnt/β-catenin Signaling Pathway,” Cell Death & Disease 12, no. 1 (2021): 105.

[351] Y. Wang, B. He, Y. Dong, et al., “Homeobox-A13 Acts as a Functional Prognostic and Diagnostic Biomarker via Regulating P53 and Wnt Signaling Pathways in Lung Cancer,” Cancer Biomarkers 31, no. 3 (2021): 239–254.

[352] A. Lahalle, M. Lacroix, C. De Blasio, M. Y. Cissé, and L. K. Linares, “Le Cam L. The p53 Pathway and Metabolism: The Tree That Hides the Forest,” Cancers 13, no. 1 (2021): 133.

[353] Y. Gu, J. Gu, K. Shen, et al., “HOXA13 promotes Colon Cancer Progression Through β-catenin-dependent WNT Pathway,” Experimental Cell Research 395, no. 2 (2020): 112238.

[354] J. Zhang, S. Zhang, X. Li, F. Zhang, and L. Zhao, “HOXB5 promotes the Progression of Breast Cancer Through Wnt/Beta-catenin Pathway,” Pathology-Research and Practice 224 (2021): 153117.

[355] C.-S. Hong, O. Jeong, Z. Piao, et al., “HOXB5 induces Invasion and Migration Through Direct Transcriptional Up-regulation of β-catenin in human Gastric Carcinoma,” Biochemical Journal 472, no. 3 (2015): 393–403.

[356] D. X. Nguyen, A. C. Chiang, X. H.-F. Zhang, et al., “WNT/TCF Signaling Through LEF1 and HOXB9 Mediates Lung Adenocarcinoma Metastasis,” Cell 138, no. 1 (2009): 51–62.

[357] T. Wang, H. Guo, Q. Li, et al., “The AMPK-HOXB9-KRAS Axis Regulates Lung Adenocarcinoma Growth in Response to Cellular Energy Alterations,” Cell Reports 40, no. 8 (2022): 111210.

[358] O.-S. Kwon, E. Oh, J.-R. Park, et al., “GalNAc-T14 Promotes Metastasis Through Wnt Dependent HOXB9 Expression in Lung Adenocarcinoma,” Oncotarget 6, no. 39 (2015): 41916.

[359] J. Wang, Q. Yang, M. Tang, and W. Liu, “Validation and Analysis of Expression, Prognosis and Immune Infiltration of WNT Gene family in Non-Small Cell Lung Cancer,” Frontiers in Oncology 12 (2022): 911316.

[360] F. Yu, C. Yu, F. Li, et al., “Wnt/β-catenin Signaling in Cancers and Targeted Therapies,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 307.

[361] J. Okamoto, T. Hirata, Z. Chen, et al., “EMX2 is Epigenetically Silenced and Suppresses Growth in human Lung Cancer,” Oncogene 29, no. 44 (2010): 5969–5975.

[362] X. Liu, X. Zhang, Q. Zhan, M. V. Brock, J. G. Herman, and M. Guo, “CDX2 serves as a Wnt Signaling Inhibitor and Is Frequently Methylated in Lung Cancer,” Cancer Biology & Therapy 13, no. 12 (2012): 1152–1157.

[363] M. P. Jimenez-García, A. Lucena-Cacace, D. Otero-Albiol, and A. Carnero, “Empty Spiracles Homeobox Genes EMX1 and EMX2 Regulate WNT Pathway Activation in Sarcomagenesis,” Journal of Experimental & Clinical Cancer Research 40, no. 1 (2021): 247.

[364] Y. Chen, T. Knösel, F. Ye, M. Pacyna-Gengelbach, N. Deutschmann, and I. Petersen, “Decreased PITX1 Homeobox Gene Expression in human Lung Cancer,” Lung Cancer 55, no. 3 (2007): 287–294.

[365] R. A. Alharbi, R. Pettengell, H. S. Pandha, and R. Morgan, “The Role of HOX Genes in Normal Hematopoiesis and Acute Leukemia,” Leukemia 27, no. 5 (2013): 1000–1008.

[366] F. Bray, M. Laversanne, H. Sung, et al., “Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 74, no. 3 (2024): 229–263.

[367] R. L. Siegel, A. N. Giaquinto, and A. Jemal, “Cancer Statistics, 2024,” CA: A Cancer Journal for Clinicians 74, no. 1 (2024): 12–49.

[368] R. L. Siegel, A. N. Giaquinto, and A. Jemal, “Cancer Statistics, 2024,” CA: A Cancer Journal for Clinicians 74, no. 1 (2024).

[369] H. Surendran, T. Palaniyandi, S. Viswanathan, et al., “Role of Homeobox d10 Gene Targeted Signaling Pathways in Cancers,” Pathology-Research and Practice 248 (2023): 154643.

[370] P. H. Hoang and M. T. Landi, “DNA Methylation in Lung Cancer: Mechanisms and Associations With Histological Subtypes, Molecular Alterations, and Major Epidemiological Factors,” Cancers 14, no. 4 (2022): 961.

[371] Y. Yang, J. Huang, Q. Wang, J. Li, L. Yu, and X. Xie, “Clinicopathologic and Prognostic Implications of HOXA Gene and Its Associated Long-noncoding RNAs Expression in Non-small Cell Carcinoma: A Meta-analysis,” Medicine 103, no. 32 (2024): e38087.

[372] L. Plowright, K. Harrington, H. Pandha, and R. Morgan, “HOX Transcription Factors Are Potential Therapeutic Targets in Non-small-cell Lung Cancer (targeting HOX genes in lung cancer),” British Journal of Cancer 100, no. 3 (2009): 470–475.

[373] C. Kappen, “Hox Genes in the Lung,” American Journal of Respiratory Cell and Molecular Biology 15, no. 2 (1996): 156–162.

[374] Y. Zhang, C. W-j, and G. T-q, “Clinical Significance and Effect of lncRNA HOXA11-AS in NSCLC: A Study Based on Bioinformatics, in Vitro and in Vivo Verification,” Scientific Reports 7, no. 1 (2017): 5567.

[375] Y. Zhang, H. E. R-q, and D. Y-w, “Comprehensive Analysis of the Long Noncoding RNA HOXA11-AS Gene Interaction Regulatory Network in NSCLC Cells,” Cancer Cell International 16 (2016): 1–20.

[376] W. Yuan, X. Zhang, Y. Xu, S. Li, Y. Hu, and S. Wu, “Role of HOXB7 in Regulation of Progression and Metastasis of human Lung Adenocarcinoma,” Molecular Carcinogenesis 53, no. 1 (2014): 49–57.

[377] L. Zhuang, W. Li, K. Li, Y. Mao, C. Gao, and C. Zhang, “HoxB7 PROMOTES GROWTH and METASTASIS of LUNG ADENOCARCINOMA CELLS through REGULATION of the TGF-β/SMAD3 SIGNALING,” Journal of Biological Regulators and Homeostatic Agents 29, no. 3 (2015): 601–608.

[378] B.-L. Gan, R.-Q. He, Y. Zhang, D.-M. Wei, X.-H. Hu, and G. Chen, “Downregulation of HOXA3 in Lung Adenocarcinoma and Its Relevant Molecular Mechanism Analysed by RT-qPCR, TCGA and in Silico Analysis,” International Journal of Oncology 53, no. 4 (2018): 1557–1579.

[379] H. Liu, M. Zhang, S. Xu, et al., “HOXC8 promotes Proliferation and Migration Through Transcriptional Up-regulation of TGFβ1 in Non-small Cell Lung Cancer,” Oncogenesis 7, no. 2 (2018): 1.

[380] M. Shiraishi, A. Sekiguchi, A. J. Oates, M. J. Terry, and Y. Miyamoto, “HOX Gene Clusters Are Hotspots of De Novo Methylation in CpG Islands of human Lung Adenocarcinomas,” Oncogene 21, no. 22 (2002): 3659–3662.

[381] A. Ooki, Z. Maleki, J.-C. J. Tsay, et al., “A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non–small Cell Lung Cancer and Serum DNA,” Clinical Cancer Research 23, no. 22 (2017): 7141–7152.

[382] S. Fang, H. Gao, Y. Tong, et al., “Long Noncoding RNA-HOTAIR Affects Chemoresistance by Regulating HOXA1 Methylation in Small Cell Lung Cancer Cells,” Laboratory Investigation 96, no. 1 (2016): 60–68.

[383] H. Li, X. Wang, M. Zhang, M. Wang, J. Zhang, and S. Ma, “Identification of HOXA1 as a Novel Biomarker in Prognosis of Head and Neck Squamous Cell Carcinoma,” Frontiers in Molecular Biosciences 7 (2021): 602068.

[384] J. A. Tsou, J. S. Galler, K. D. Siegmund, et al., “Identification of a Panel of Sensitive and Specific DNA Methylation Markers for Lung Adenocarcinoma,” Molecular Cancer 6 (2007): 1–13.

[385] Y. Zhang, X.-J. Li, R.-Q. He, et al., “Upregulation of HOXA1 Promotes Tumorigenesis and Development of Non‑Small Cell Lung Cancer: A Comprehensive Investigation Based on Reverse Transcription-quantitative Polymerase Chain Reaction and Bioinformatics Analysis,” International Journal of Oncology 53, no. 1 (2018): 73–86.

[386] R. Chen, B. Chen, D. Li, et al., “HOTAIR Contributes to Chemoresistance by Activating NF-κB Signaling in Small-cell Lung Cancer,” International Journal of Clinical and Experimental Pathology 12, no. 8 (2019): 2997.

[387] S. Fang, Y. Shen, B. Chen, et al., “H3K27me3 induces Multidrug Resistance in Small Cell Lung Cancer by Affecting HOXA1 DNA Methylation via Regulation of the lncRNA HOTAIR,” Annals of Translational Medicine 6, no. 22 (2018): 440.

[388] W. Huang, H. Li, Q. Yu, W. Xiao, and D. O. Wang, “LncRNA-mediated DNA Methylation: An Emerging Mechanism in Cancer and Beyond,” Journal of Experimental & Clinical Cancer Research 41, no. 1 (2022): 100.

[389] C. Zhu, X. Wang, Y. Wang, and K. Wang, “Functions and Underlying Mechanisms of lncRNA HOTAIR in Cancer Chemotherapy Resistance,” Cell Death Discovery 8, no. 1 (2022): 383.

[390] M. H. Park and J. T. Hong, “Roles of NF-κB in Cancer and Inflammatory Diseases and Their Therapeutic Approaches,” Cells 5, no. 2 (2016): 15.

[391] P. Huang, B. Ye, Y. Yang, J. Shi, and H. Zhao, “MicroRNA-181 Functions as a Tumor Suppressor in Non-small Cell Lung Cancer (NSCLC) by Targeting Bcl-2,” Tumor Biology 36 (2015): 3381–3387.

[392] F. Xiao, Y. Bai, Z. Chen, et al., “Downregulation of HOXA1 Gene Affects Small Cell Lung Cancer Cell Survival and Chemoresistance Under the Regulation of miR-100,” European Journal of Cancer 50, no. 8 (2014): 1541–1554.

[393] W. Han, X. Ren, Y. Yang, H. Li, L. Zhao, and Z. Lin, “microRNA-100 Functions as a Tumor Suppressor in Non-small Cell Lung Cancer via Regulating Epithelial-mesenchymal Transition and Wnt/β-catenin by Targeting HOXA1,” Thoracic Cancer 11, no. 6 (2020): 1679–1688.

[394] G. Heller, V. N. Babinsky, B. Ziegler, et al., “Genome-wide CpG Island Methylation Analyses in Non-small Cell Lung Cancer Patients,” Carcinogenesis 34, no. 3 (2013): 513–521.

[395] M. Jiang, X. Ye, D. Shi, Q. Lin, F. Huang, and Y. Li, “LncRNA-LINC00472 Suppresses the Malignant Progression of Non-small Cell Lung Cancer via Modulation of the miRNA-1275/Homeobox A2 Axis,” Advances in Clinical and Experimental Medicine 33, no. 3 (2024): 283–297.

[396] I. Daugaard, D. Dominguez, T. E. Kjeldsen, et al., “Identification and Validation of Candidate Epigenetic Biomarkers in Lung Adenocarcinoma,” Scientific Reports 6, no. 1 (2016): 35807.

[397] C.-J. Chang, Y.-L. Chen, C.-H. Hsieh, et al., “HOXA5 and p53 Cooperate to Suppress Lung Cancer Cell Invasion and Serve as Good Prognostic Factors in Non-small Cell Lung Cancer,” Journal of Cancer 8, no. 6 (2017): 1071.

[398] L. Jeannotte, F. Gotti, and K. Landry-Truchon, “Hoxa5: A Key Player in Development and Disease,” Journal of Developmental Biology 4, no. 2 (2016): 13.

[399] M.-L. Zhang, F.-Q. Nie, M. Sun, et al., “HOXA5 indicates Poor Prognosis and Suppresses Cell Proliferation by Regulating p21 Expression in Non Small Cell Lung Cancer,” Tumor Biology 36 (2015): 3521–3531.

[400] X.-H. Liu, K.-H. Lu, K.-M. Wang, et al., “MicroRNA-196a Promotes Non-small Cell Lung Cancer Cell Proliferation and Invasion Through Targeting HOXA5,” BMC Cancer 12 (2012): 1–12.

[401] C.-C. Wang, K.-Y. Su, H.-Y. Chen, et al., “HOXA5 inhibits Metastasis via Regulating Cytoskeletal Remodelling and Associates With Prolonged Survival in Non-small-cell Lung Carcinoma,” PLoS ONE 10, no. 4 (2015): e0124191.

[402] D. S. Kim, M. J. Kim, J. Y. Lee, et al., “Epigenetic Inactivation of Homeobox A5 Gene in Nonsmall Cell Lung Cancer and Its Relationship With Clinicopathological Features,” Molecular Carcinogenesis: Published in Cooperation with the University of Texas MD Anderson Cancer Center 48, no. 12 (2009): 1109–1115.

[403] C. Chen, X. Huang, W. Yin, et al., “Ultrasensitive DNA Hypermethylation Detection Using Plasma for Early Detection of NSCLC: A Study in Chinese Patients With Very Small Nodules,” Clinical Epigenetics 12 (2020): 1–11.

[404] Q. Chen, Q. Pan, H. Gao, Y. Wang, and X. Zhong, “miR-17-5p/HOXA7 Is a Potential Driver for Brain Metastasis of Lung Adenocarcinoma Related to Ferroptosis Revealed by Bioinformatic Analysis,” Frontiers in Neurology 13 (2022): 878947.

[405] Q. Pan, Z. Tang, J. Zheng, L. Yan, Y. Liang, and Q. Chen, “Long Non-coding RNA HCP5 Affects Ferroptosis in Lung Adenocarcinoma Cells Through miR-17-5p/HOXA7 Axis,” Current Cancer Drug Targets (2023).

[406] S. W. Wen, R. F. Andersen, K. Rasmussen, et al., “Validating Methylated HOXA9 in Bronchial Lavage as a Diagnostic Tool in Patients Suspected of Lung Cancer,” Cancers 13, no. 16 (2021): 4223.

[407] B. Li, Q. Huang, and G. Wei, “The Role of HOX Transcription Factors in Cancer Predisposition and Progression,” Cancers (Basel) 11 (2019): 528.

[408] Q. Wu, R. A. Lothe, T. Ahlquist, et al., “DNA Methylation Profiling of Ovarian Carcinomas and Their in Vitro Models Identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as Novel Targets,” Molecular Cancer 6 (2007): 1–11.

[409] S.-M. Park, E.-Y. Choi, M. Bae, J. K. Choi, and Y.-J. Kim, “A Long-range Interactive DNA Methylation Marker Panel for the Promoters of HOXA9 and HOXA10 Predicts Survival in Breast Cancer Patients,” Clinical Epigenetics 9, no. 1 (2017): 1–11.

[410] F. Liu, H. Zhang, S. Lu, et al., “Quantitative Assessment of Gene Promoter Methylation in Non‑Small Cell Lung Cancer Using Methylation‑Sensitive High‑Resolution Melting,” Oncology Letters 15, no. 5 (2018): 7639–7648.

[411] S.-H. Hwang, K. U. Kim, J.-E. Kim, et al., “Detection of HOXA9 Gene Methylation in Tumor Tissues and Induced Sputum Samples From Primary Lung Cancer Patients,” Clinical Chemistry and Laboratory Medicine 49, no. 4 (2011): 699–704.

[412] J. A. Hwang, B. B. Lee, Y. Kim, et al., “HOXA9 inhibits Migration of Lung Cancer Cells and Its Hypermethylation Is Associated With Recurrence in Non-small Cell Lung Cancer,” Molecular Carcinogenesis 54, no. S1 (2015): E72–E80.

[413] S. P. Nunes, F. Diniz, C. Moreira-Barbosa, et al., “Subtyping Lung Cancer Using DNA Methylation in Liquid Biopsies,” Journal of Clinical Medicine 8, no. 9 (2019): 1500.

[414] J. Wrangle, E. O. Machida, L. Danilova, et al., “Functional Identification of Cancer-specific Methylation of CDO1, HOXA9, and TAC1 for the Diagnosis of Lung Cancer,” Clinical Cancer Research 20, no. 7 (2014): 1856–1864.

[415] A. Hata, T. Nakajima, K. Matsusaka, et al., “A Low DNA Methylation Epigenotype in Lung Squamous Cell Carcinoma and Its Association With Idiopathic Pulmonary Fibrosis and Poorer Prognosis,” International Journal of Cancer 146, no. 2 (2020): 388–399.

[416] A. Hulbert, I. Jusue-Torres, A. Stark, et al., “Early Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and Sputum,” Clinical Cancer Research 23, no. 8 (2017): 1998–2005.

[417] A. Vicente, F. A. de Souza Santos, W. Y. Hirai, et al., “HOXA9 methylation Is Not Associated With Survival in Brazilian Patients With Lung Adenocarcinoma,” Clinical Epigenetics 17, no. 1 (2025): 1–7.

[418] Y.-N. Guo, B. Luo, W.-J. Chen, et al., “Comprehensive Clinical Implications of Homeobox A10 in 3,199 Cases of Non-small Cell Lung Cancer Tissue Samples Combining qRT-PCR, RNA Sequencing and Microarray Data,” American Journal of Translational Research 11, no. 1 (2019): 45.

[419] J.-H. Chung, H. J. Lee, B.-H. Kim, N.-Y. Cho, and G. H. Kang, “DNA Methylation Profile During Multistage Progression of Pulmonary Adenocarcinomas,” Virchows Archiv 459 (2011): 201–211.

[420] R. Calvo, J. West, W. Franklin, et al., “Altered HOX and WNT7A Expression in human Lung Cancer,” Proceedings of the National Academy of Sciences of the United States of America 97, no. 23 (2000): 12776–12781.

[421] Y. Wei, Z. Yan, C. Wu, et al., “Integrated Analysis of Dosage Effect lncRNAs in Lung Adenocarcinoma Based on Comprehensive Network,” Oncotarget 8, no. 42 (2017): 71430.

[422] T. Lu, T. Qiu, B. Han, et al., “Circular RNA circCSNK1G3 Induces HOXA10 Signaling and Promotes the Growth and Metastasis of Lung Adenocarcinoma Cells Through Hsa-miR-143-3p Sponging,” Cellular Oncology 44 (2021): 297–310.

[423] Q. S. Yang, B. Li, G. Xu, et al., “Long Noncoding RNA LINC00483/microRNA-144 Regulates Radiosensitivity and Epithelial–mesenchymal Transition in Lung Adenocarcinoma by Interacting With HOXA10,” Journal of Cellular Physiology 234, no. 7 (2019): 11805–11821.

[424] X. J-Y, H. C, W. Wang, L. I. H-b, M. Sun, and M. Xie, “HOXA11-AS: A Novel Regulator in human Cancer Proliferation and Metastasis,” OncoTargets and Therapy (2018): 4387–4393.

[425] C. W. Lu, D. D. Zhou, T. Xie, et al., “HOXA 11 Antisense Long Noncoding RNA (HOXA 11-AS): A Promising Lnc RNA in human Cancers,” Cancer Medicine 7, no. 8 (2018): 3792–3799.

[426] T. Ma, Y. Hu, Y. Guo, and B. Yan, “Tumor-Promoting Activity of Long Noncoding RNA LINC00466 in Lung Adenocarcinoma via miR-144–Regulated HOXA10 Axis,” The American Journal of Pathology 189, no. 11 (2019): 2154–2170.

[427] J. Hou, Y. Wang, H. Zhang, Y. Hu, X. Xin, and X. Li, “Silencing of LINC00461 Enhances Radiosensitivity of Lung Adenocarcinoma Cells by Down-regulating HOXA10 via microRNA-195,” Journal of Cellular and Molecular Medicine 24, no. 5 (2020): 2879–2890.

[428] H. Zhu, W. Yang, Q. Cheng, and S. Yang, “Circ_0010235 regulates HOXA10 Expression to Promote Malignant Phenotypes and Radioresistance in Non-small Cell Lung Cancer Cells via Decoying miR-588,” Balkan Medical Journal 39, no. 4 (2022): 255.

[429] J.-A. Hwang, B. B. Lee, Y. Kim, et al., “HOXA11 hypermethylation Is Associated With Progression of Non-small Cell Lung Cancer,” Oncotarget 4, no. 12 (2013): 2317.

[430] M. Bibikova, Z. Lin, L. Zhou, et al., “High-throughput DNA Methylation Profiling Using Universal Bead Arrays,” Genome Research 16, no. 3 (2006): 383–393.

[431] S. A. Selamat, J. S. Galler, A. D. Joshi, et al., “DNA Methylation Changes in atypical Adenomatous Hyperplasia, Adenocarcinoma in Situ, and Lung Adenocarcinoma,” PLoS ONE 6, no. 6 (2011): e21443.

[432] Y. Zhang, Y. Yuan, Y. Li, P. Zhang, P. Chen, and S. Sun, “An Inverse Interaction Between HOXA11 and HOXA11-AS Is Associated With Cisplatin Resistance in Lung Adenocarcinoma,” Epigenetics 14, no. 10 (2019): 949–960.

[433] T. Sato, E. Arai, T. Kohno, et al., “DNA Methylation Profiles at Precancerous Stages Associated With Recurrence of Lung Adenocarcinoma,” PLoS ONE 8, no. 3 (2013): e59444.

[434] J. Geng, J. Sun, Q. Lin, et al., “Methylation Status of NEUROG2 and NID2 Improves the Diagnosis of Stage I NSCLC,” Oncology Letters 3, no. 4 (2012): 901–906.

[435] T. A. Rauch, X. Zhong, X. Wu, et al., “High-resolution Mapping of DNA Hypermethylation and Hypomethylation in Lung Cancer,” Proceedings of the National Academy of Sciences of the United States of America 105, no. 1 (2008): 252–257.

[436] M. Ji, H. Guan, C. Gao, B. Shi, and P. Hou, “Highly Frequent Promoter Methylation and PIK3CA Amplification in Non-small Cell Lung Cancer (NSCLC),” BMC Cancer 11 (2011): 1–11.

[437] C. Du, L. Tan, X. Xiao, et al., “Detection of the DNA Methylation of Seven Genes Contribute to the Early Diagnosis of Lung Cancer,” Journal of Cancer Research and Clinical Oncology 150, no. 2 (2024): 77.

[438] M. Yan, X. Yin, L. Zhang, Y. Cui, and X. Ma, “High Expression of HOXB3 Predicts Poor Prognosis and Correlates With Tumor Immunity in Lung Adenocarcinoma,” Molecular Biology Reports (2022): 1–12.

[439] H. Du, B. Yn, C. Liu, A. Zhong, Y. Niu, and X. Tang, “miR‑139‑5p Enhances Cisplatin Sensitivity in Non‑Small Cell Lung Cancer Cells by Inhibiting Cell Proliferation and Promoting Apoptosis via the Targeting of Homeobox Protein Hox‑B2,” Molecular Medicine Reports 23, no. 2 (2021): 1–1.

[440] X. Liang, Q. Wu, Y. Wang, and S. Li, “MicroRNAs as Early Diagnostic Biomarkers for Non-small Cell Lung Cancer,” Oncology Reports 49, no. 1 (2022): 8.

[441] N. Nakamura, T. Yoshimi, and T. Miura, “Increased Gene Expression of Lung Marker Proteins in the Homeobox B3-overexpressed Fetal Lung Cell Line M3E3/C3,” Cell Growth & Differentiation 13, no. 4 (2002): 195–203.

[442] L. Zhang, Z. Xu, S. Wu, Y. ahmed Muad, W. Peng, and L. Ye, “Methylation-regulated Tumor Suppressor Gene HOXB4 Inhibits human Lung Adenocarcinoma A549 Cell Invasion and Metastasis Through the RAP1 Signaling Pathway,” Translational Cancer Research 14, no. 10 (2025): 6483–6496.

[443] S. Liu, K. Jin, and Y. Hui, “HOXB7 promotes Malignant Progression by Activating the TGFβ Signaling Pathway,” Cancer Research 75, no. 4 (2015): 709–719.

[444] A. B. Baba, B. Rah, G. R. Bhat, et al., “Transforming Growth Factor-beta (TGF-β) Signaling in Cancer-A Betrayal Within,” Frontiers in Pharmacology 13 (2022): 791272.

[445] E. Zhang, D. Yin, M. Sun, et al., “P53-regulated Long Non-coding RNA TUG1 Affects Cell Proliferation in human Non-small Cell Lung Cancer, Partly Through Epigenetically Regulating HOXB7 Expression,” Cell Death & Disease 5, no. 5 (2014): e1243–e1243.

[446] Y. Liang, H. Lin, Z. Jiang, Q. Zhao, R. Cui, and S. Li, “HOXB8 mediates Resistance to cetuximab in Colorectal Cancer Cells Through Activation of the STAT3 Pathway,” Discover Oncology 15, no. 1 (2024): 1–12.

[447] H. Zheng, C. Li, Z. Li, et al., “HOXB9 enhances the Ability of Lung Cancer Cells to Penetrate the Blood-brain Barrier,” Aging (Albany NY) 13, no. 4 (2020): 4999.

[448] J. Zhan, P. Wang, M. Niu, et al., “High Expression of Transcriptional Factor HoxB9 Predicts Poor Prognosis in Patients With Lung Adenocarcinoma,” Histopathology 66, no. 7 (2015): 955–965.

[449] T. Hayashida, F. Takahashi, N. Chiba, et al., “HOXB9, a Gene Overexpressed in Breast Cancer, Promotes Tumorigenicity and Lung Metastasis,” Proceedings of the National Academy of Sciences of the United States of America 107, no. 3 (2010): 1100–1105.

[450] J. Xiao, Y. Li, Y. Liu, et al., “The Involvement of homeobox-C 4 in Predicting Prognosis and Unraveling Immune Landscape Across Multiple Cancers via Integrated Analysis,” Frontiers in Genetics 13 (2022): 1021473.

[451] M. Šutić, B. Dmitrović, A. Jakovčević, et al., “Transcriptomic Profiling for Prognostic Biomarkers in Early-Stage Squamous Cell Lung Cancer (SqCLC),” Cancers 16, no. 4 (2024): 720.

[452] Y. Yang, X. Tang, X. Song, et al., “Evidence for an Oncogenic Role of HOXC6 in human Non-small Cell Lung Cancer,” PeerJ 7 (2019): e6629.

[453] W. He, M. Qin, Y. Cai, et al., “Downregulation of HOXC6 by miR-27a Ameliorates Gefitinib Resistance in Non-small Cell Lung Cancer,” American Journal of Cancer Research 11, no. 9 (2021): 4329.

[454] M. Xin, H. Peng, and L. Zhang, “Exploring the Prognosis Value, Immune Correlation, and Drug Responsiveness Prediction of Homeobox C6 (HOXC6) in Lung Adenocarcinoma,” Discover Oncology 15, no. 1 (2024): 393.

[455] A.-L. Huang, S.-G. Liu, W.-J. Qi, et al., “TGF-β1 Protein Expression in Non-small Cell Lung Cancers Is Correlated With Prognosis,” Asian Pacific Journal of Cancer Prevention 15, no. 19 (2014): 8143–8147.

[456] S. Aftabi, A. Barzegar Behrooz, M. Cordani, et al., “Therapeutic Targeting of TGF-β in Lung Cancer,” The FEBS Journal (2024).

[457] J. Zhang, M. Yang, D. Li, et al., “Homeobox C8 Is a Transcriptional Repressor of E-cadherin Gene Expression in Non-small Cell Lung Cancer,” The International Journal of Biochemistry & Cell Biology 114 (2019): 105557.

[458] R. Bi, W. Wei, Y. Lu, et al., “High hsa_circ_0020123 Expression Indicates Poor Progression to Non-small Cell Lung Cancer by Regulating the miR-495/HOXC9 Axis,” Aging (Albany NY) 12, no. 17 (2020): 17343.

[459] Q. Lin, J. Geng, K. Ma, et al., “RASSF1A, APC, ESR1, ABCB1 and HOXC9, but Not p16INK4A, DAPK1, PTEN and MT1G Genes Were Frequently Methylated in the Stage I Non-small Cell Lung Cancer in China,” Journal of Cancer Research and Clinical Oncology 135 (2009): 1675–1684.

[460] P. P. Anglim, J. S. Galler, M. N. Koss, et al., “Identification of a Panel of Sensitive and Specific DNA Methylation Markers for Squamous Cell Lung Cancer,” Molecular Cancer 7, no. 1 (2008): 1–13.

[461] L. Liu, Z. Zhang, C. Jiang, et al., “HOXC9 characterizes a Suppressive Tumor Immune Microenvironment and Integration With Multiple Immune Biomarkers Predicts Response to PD-1 Blockade plus Chemotherapy in Lung Adenocarcinoma,” Aging (Albany NY) 16, no. 5 (2024): 4841.

[462] Y. Liu, L. Jing, and J. Zhang, “circRNA-mediated Upregulation of HOXC9 Is Correlated With Poor Outcome and Immune Microenvironment Infiltrates in LUAD,” Biochemical and Biophysical Research Communications 635 (2022): 128–135.

[463] W. Liu, Y. Sun, Y. Huo, L. Zhang, N. Zhang, and M. Yang, “Circular RNAs in Lung Cancer: Implications for Preventing Therapeutic Resistance,” Ebiomedicine 107 (2024): 105309.

[464] S. L. Guerra, O. Maertens, R. Kuzmickas, et al., “A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-mutant Lung Cancers,” Cancer Cell 37, no. 5 (2020): 705–719. e6.

[465] X. Tan, Z. Li, H. Xie, et al., “Pan-cancer Analysis of Homeodomain-containing Gene C10 and Its Carcinogenesis in Lung Adenocarcinoma,” Aging (Albany NY) 15, no. 24 (2023): 15243.

[466] K. Li, B. Yang, Y. Du, et al., “The HOXC10/NOD1/ERK Axis Drives Osteolytic Bone Metastasis of Pan-KRAS-mutant Lung Cancer,” Bone Research 12, no. 1 (2024): 47.

[467] H. Adderley, F. H. Blackhall, and C. R. Lindsay, “KRAS-mutant Non-small Cell Lung Cancer: Converging Small Molecules and Immune Checkpoint Inhibition,” EBioMedicine 41 (2019): 711–716.

[468] P. Radeczky, Z. Megyesfalvi, V. Laszlo, et al., “The Effects of Bisphosphonate and Radiation Therapy in Bone-metastatic Lung Adenocarcinoma: The Impact of KRAS Mutation,” Translational Lung Cancer Research 10, no. 2 (2021): 675.

[469] Y. Cheng, Z. Song, X. Fang, and Z. Tang, “Polycomb Repressive Complex 2 and Its Core Component EZH2: Potential Targeted Therapeutic Strategies for Head and Neck Squamous Cell Carcinoma,” Clinical Epigenetics 16, no. 1 (2024): 54.

[470] M. Serresi, G. Gargiulo, N. Proost, et al., “Polycomb Repressive Complex 2 Is a Barrier to KRAS-driven Inflammation and Epithelial-mesenchymal Transition in Non-small-cell Lung Cancer,” Cancer Cell 29, no. 1 (2016): 17–31.

[471] X. Peng, X. Liu, W. Hu, et al., “HOXC11 drives Lung Adenocarcinoma Progression Through Transcriptional Regulation of SPHK1,” Cell Death & Disease 14, no. 2 (2023): 153.

[472] B. Sun, J. Hua, H. Cui, H. Liu, K. Zhang, and H. Zhou, “MicroRNA-1197 Downregulation Inhibits Proliferation and Migration in human Non-small Cell Lung Cancer Cells by Upregulating HOXC11,” Biomedicine & Pharmacotherapy 117 (2019): 109041.

[473] R. R. Rasmi, K. M. Sakthivel, and C. Guruvayoorappan, “NF-κB Inhibitors in Treatment and Prevention of Lung Cancer,” Biomedicine & Pharmacotherapy 130 (2020): 110569.

[474] T. HU, P. Gao, and M. Jiang, et al. Prediction of the diagnostic and prognostic values of homeobox family in lung cancer using bioinformatics. (2022).

[475] B. Liu, J. Li, J.-M. Li, G.-Y. Liu, and Y.-S. Wang, “HOXC-AS2 Mediates the Proliferation, Apoptosis, and Migration of Non-small Cell Lung Cancer by Combining With HOXC13 Gene,” Cell Cycle 20, no. 2 (2021): 236–246.

[476] Y. Yao, J. Luo, Q. Sun, et al., “HOXC13 promotes Proliferation of Lung Adenocarcinoma via Modulation of CCND1 and CCNE1,” American Journal of Cancer Research 7, no. 9 (2017): 1820.

[477] X. Wang, X. Liu, Y. Yang, and D. Yang, “Cyclin D1 Mediated by the Nuclear Translocation of Nuclear Factor Kappa B Exerts an Oncogenic Role in Lung Cancer,” Bioengineered 13, no. 3 (2022): 6866–6879.

[478] G. Ma, L. Yang, J. Dong, and L. Zhang, “CCNE1 promotes Progression and Is Associated With Poor Prognosis in Lung Adenocarcinoma,” Current Pharmaceutical Biotechnology 23, no. 9 (2022): 1168–1178.

[479] M. A. Ullah, M. Farzana, M. S. Islam, R. Moni, U. S. Zohora, and M. S. Rahman, “Identification of the Prognostic and Therapeutic Values of Cyclin E1 (CCNE1) Gene Expression in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma: A Database Mining Approach,” Heliyon 8, no. 9 (2022): e10367.

[480] L. Wang, C. Qiao, L. Cao, et al., “Significance of HOXD Transcription Factors family in Progression, Migration and Angiogenesis of Cancer,” Critical Reviews in Oncology/Hematology 179 (2022): 103809.

[481] X. Hu, S. Zhang, X. Zhang, H. Liu, Y. Diao, and L. Li, “HOXD1 inhibits Lung Adenocarcinoma Progression and Is Regulated by DNA Methylation,” Oncology Reports 52, no. 6 (2024): 173.

[482] V. Constâncio, S. P. Nunes, C. Moreira-Barbosa, et al., “Early Detection of the Major Male Cancer Types in Blood-based Liquid Biopsies Using a DNA Methylation Panel,” Clinical Epigenetics 11 (2019): 1–18.

[483] L. Han, G. Xu, C. Xu, B. Liu, and D. Liu, “Potential Prognostic Biomarkers Identified by DNA Methylation Profiling Analysis for Patients With Lung Adenocarcinoma,” Oncology Letters 15, no. 3 (2018): 3552–3557.

[484] Y. J. Miyazaki, J.-I. Hamada, M. Tada, et al., “HOXD3 enhances Motility and Invasiveness Through the TGF-β-dependent and-independent Pathways in A549 Cells,” Oncogene 21, no. 5 (2002): 798–808.

[485] J. I. Hamada, T. Omatsu, F. Okada, et al., “Overexpression of Homeobox Gene HOXD3 Induces Coordinate Expression of Metastasis-related Genes in human Lung Cancer Cells,” International Journal of Cancer 93, no. 4 (2001): 516–525.

[486] A. Olson, V. Le, J. Aldahl, et al., “The Comprehensive Role of E-cadherin in Maintaining Prostatic Epithelial Integrity During Oncogenic Transformation and Tumor Progression,” PLoS Genetics 15, no. 10 (2019): e1008451.

[487] H. Ohta, J.-I. Hamada, and M. Tada, “HOXD3-overexpression Increases Integrin αvβ3 Expression and Deprives E-cadherin While It Enhances Cell Motility in A549 Cells,” Clinical & Experimental Metastasis 23 (2006): 381–390.

[488] E. Küçükköse, J. Laoukili, A. N. Gorelick, et al., “Lymphatic Invasion of Plakoglobin-dependent Tumor Cell Clusters Drives Formation of Polyclonal Lung Metastases in Colon Cancer,” Gastroenterology 165, no. 2 (2023): 429–444. e15.

[489] Z.-Q. Cao, Z. Wang, and P. Leng, “Aberrant N-cadherin Expression in Cancer,” Biomedicine & Pharmacotherapy 118 (2019): 109320.

[490] K. M. Mrozik, O. W. Blaschuk, C. M. Cheong, A. C. W. Zannettino, and K. Vandyke, “N-cadherin in Cancer Metastasis, Its Emerging Role in Haematological Malignancies and Potential as a Therapeutic Target in Cancer,” BMC Cancer 18, no. 1 (2018): 939.

[491] Y. Liu, L. Miao, R. Ni, et al., “microRNA-520a-3p Inhibits Proliferation and Cancer Stem Cell Phenotype by Targeting HOXD8 in Non-small Cell Lung Cancer,” Oncology Reports 36, no. 6 (2016): 3529–3535.

[492] W. Zhu, J.-P. Wang, Q.-Z. Meng, F. Zhu, and X.-F. Hao, “MiR-142-5p Reverses the Resistance to gefitinib Through Targeting HOXD8 in Lung Cancer Cells,” European Review for Medical & Pharmacological Sciences 24, no. 8 (2020): 4306–4313.

[493] M. Sakamoto and T. Patil, “MET Alterations in Advanced Non-small Cell Lung Cancer,” Lung Cancer 178 (2023): 254–268.

[494] Y. Zhang, M. Xia, and K. Jin, “Function of the c-Met Receptor Tyrosine Kinase in Carcinogenesis and Associated Therapeutic Opportunities,” Molecular Cancer 17 (2018): 1–14.

[495] J. He, M. Jiang, J. Liu, et al., “Homeobox D9 Drives the Malignant Phenotypes and Enhances the Programmed Death Ligand-1 Expression in Non-small Cell Lung Cancer Cells via Binding to Angiopoietin-2 Promoter,” World Journal of Surgical Oncology 21, no. 1 (2023): 93.

[496] K. Wan, J. Shao, X. Liu, et al., “HOXD9 contributes to the Warburg Effect and Tumor Metastasis in Non-small Cell Lung Cancer via Transcriptional Activation of PFKFB3,” Experimental Cell Research 427, no. 1 (2023): 113583.

[497] O. Pernía, A. Sastre-Perona, C. Rodriguez-Antolín, et al., “A Novel Role for the Tumor Suppressor Gene ITF2 in Tumorigenesis and Chemotherapy Response,” Cancers 12, no. 4 (2020): 786.

[498] T. Mishina, H. Dosaka-Akita, F. Hommura, et al., “Cyclin E Expression, a Potential Prognostic Marker for Non-small Cell Lung Cancers,” Clinical Cancer Research 6, no. 1 (2000): 11–16.

[499] C. Müller-Tidow, R. Metzger, K. Kügler, et al., “Cyclin E Is the Only Cyclin-dependent Kinase 2-associated Cyclin That Predicts Metastasis and Survival in Early Stage Non-small Cell Lung Cancer,” Cancer Research 61, no. 2 (2001): 647–653.

[500] L. Zhou, H. Lan, Q. Zhou, J. Yue, and B. Liu, “Plasma Angiopoietin-2 Is Persistently Elevated After Non-small Cell Lung Cancer Surgery and Stimulates Angiogenesis in Vitro,” Medicine 95, no. 32 (2016): e4493.

[501] P. Thirusangu, U. Ray, S. Sarkar Bhattacharya, et al., “PFKFB3 regulates Cancer Stemness Through the Hippo Pathway in Small Cell Lung Carcinoma,” Oncogene 41, no. 33 (2022): 4003–4017.

[502] M. Wielscher, K. Vierlinger, U. Kegler, R. Ziesche, A. Gsur, and A. Weinhäusel, “Diagnostic Performance of Plasma DNA Methylation Profiles in Lung Cancer, Pulmonary Fibrosis and COPD,” EBioMedicine 2, no. 8 (2015): 929–936.

[503] S. Li, J. Zhang, Y. Zhao, F. Wang, Y. Chen, and X. Fei, “miR-224 Enhances Invasion and Metastasis by Targeting HOXD10 in Non-small Cell Lung Cancer Cells,” Oncology Letters 15, no. 5 (2018): 7069–7075.

[504] W. Xu, J. Lu, Q. Zhao, et al., “Genome-Wide Plasma Cell-Free DNA Methylation Profiling Identifies Potential Biomarkers for Lung Cancer,” Disease Markers 2019, no. 1 (2019): 4108474.

[505] H. Harada, K. Miyamaoto, M. Kimura, T. Ishigami, K. Taniyama, and M. Okada, “Lung Cancer Risk Stratification Using Methylation Profile in the Oral Epithelium,” Asian Cardiovascular and Thoracic Annals 27, no. 2 (2019): 87–92.

[506] T. Ohira, S. Nakagawa, J. Takeshita, H. Aburatani, and H. Kugoh, “PITX1 inhibits the Growth and Proliferation of Melanoma Cells Through Regulation of SOX family Genes,” Scientific Reports 11, no. 1 (2021): 18405.

[507] J. Zhao and Y. Xu, “PITX1 plays Essential Functions in Cancer,” Frontiers in Oncology 13 (2023): 1253238.

[508] D. Dietrich, O. Hasinger, V. Liebenberg, J. K. Field, G. Kristiansen, and A. Soltermann, “DNA Methylation of the Homeobox Genes PITX2 and SHOX2 Predicts Outcome in Non–small-cell Lung Cancer Patients,” Diagnostic Molecular Pathology 21, no. 2 (2012): 93–104.

[509] V. Sailer, E. E. Holmes, H. Gevensleben, et al., “PITX2 and PANCR DNA Methylation Predicts Overall Survival in Patients With Head and Neck Squamous Cell Carcinoma,” Oncotarget 7, no. 46 (2016): 75827.

[510] G. Bildik, X. Liang, M. N. Sutton, R. C. Bast, and Z. Lu, “DIRAS3: An Imprinted Tumor Suppressor Gene That Regulates RAS and PI3K-driven Cancer Growth, Motility, Autophagy, and Tumor Dormancy,” Molecular Cancer Therapeutics 21, no. 1 (2022): 25–37.

[511] B. Schmidt, V. Liebenberg, D. Dietrich, et al., “SHOX2 DNA Methylation Is a Biomarker for the Diagnosis of Lung Cancer Based on Bronchial Aspirates,” BMC Cancer 10, no. 1 (2010): 1–9.

[512] C. Kneip, B. Schmidt, A. Seegebarth, et al., “SHOX2 DNA Methylation Is a Biomarker for the Diagnosis of Lung Cancer in Plasma,” Journal of Thoracic Oncology 6, no. 10 (2011): 1632–1638.

[513] C. Zhang, W. Yu, L. Wang, et al., “DNA Methylation Analysis of the SHOX2 and RASSF1A Panel in Bronchoalveolar Lavage Fluid for Lung Cancer Diagnosis,” Journal of Cancer 8, no. 17 (2017): 3585.

[514] J. Zhao, Y. Lu, X. Ren, et al., “Association of the SHOX2 and RASSF1A Methylation Levels With the Pathological Evolution of Early-stage Lung Adenocarcinoma,” BMC Cancer 24, no. 1 (2024): 687.

[515] M. M. Küster, M. A. Schneider, A. M. Richter, et al., “Epigenetic Inactivation of the Tumor Suppressor IRX1 Occurs Frequently in Lung Adenocarcinoma and Its Silencing Is Associated With Impaired Prognosis,” Cancers 12, no. 12 (2020): 3528.

[516] T. Sato, E. Arai, T. Kohno, et al., “Epigenetic Clustering of Lung Adenocarcinomas Based on DNA Methylation Profiles in Adjacent Lung Tissue: Its Correlation With Smoking History and Chronic Obstructive Pulmonary Disease,” International Journal of Cancer 135, no. 2 (2014): 319–334.

[517] J. Graule, K. Uth, E. Fischer, et al., “CDX2 in Colorectal Cancer Is an Independent Prognostic Factor and Regulated by Promoter Methylation and Histone Deacetylation in Tumors of the Serrated Pathway,” Clinical Epigenetics 10 (2018): 1–12.

[518] B. Sukka-Ganesh, K. A. Mohammed, F. Kaye, E. P. Goldberg, and N. Nasreen, “Ephrin-A1 Inhibits NSCLC Tumor Growth via Induction of Cdx-2 a Tumor Suppressor Gene,” BMC Cancer 12 (2012): 1–13.

[519] P. Gao, N. Sun, T. Zhao, et al., “Identification of Prognostic Indicators, Diagnostic Markers, and Possible Therapeutic Targets Among LIM Homeobox Transcription Factors in Breast Cancer,” Cancer Innovation 1, no. 3 (2022): 252–269.

[520] Q. Yang, L. Wan, and C. Xiao, “Inhibition of LHX2 by miR‑124 Suppresses Cellular Migration and Invasion in Non‑Small Cell Lung Cancer,” Oncology Letters 14, no. 3 (2017): 3429–3436.

[521] T. Rauch, H. Li, X. Wu, and G. P. Pfeifer, “MIRA-assisted Microarray Analysis, a New Technology for the Determination of DNA Methylation Patterns, Identifies Frequent Methylation of Homeodomain-containing Genes in Lung Cancer Cells,” Cancer Research 66, no. 16 (2006): 7939–7947.

[522] X. Lin, Y. Li, J. Wang, et al., “LHX3 is an Early Stage and Radiosensitivity Prognostic Biomarker in Lung Adenocarcinoma,” Oncology Reports 38, no. 3 (2017): 1482–1490.

[523] W. Liu, X. Jiang, F. Han, et al., “LHX6 acts as a Novel Potential Tumour Suppressor With Epigenetic Inactivation in Lung Cancer,” Cell Death & Disease 4, no. 10 (2013): e882–e882.

[524] J. Yang, F. Han, W. Liu, et al., “LHX6, an Independent Prognostic Factor, Inhibits Lung Adenocarcinoma Progression Through Transcriptional Silencing of β-catenin,” Journal of Cancer 8, no. 13 (2017): 2561.

[525] Q. Wang, J. Liao, Z. He, et al., “LHX6 affects Erlotinib Resistance and Migration of EGFR-mutant Non-small-cell Lung Cancer HCC827 Cells Through Suppressing Wnt/β-catenin Signaling,” OncoTargets and Therapy 13 (2020): 10983–10994.

[526] J. Liao, J. Lin, D. Lin, et al., “Down-regulation of miR-214 Reverses Erlotinib Resistance in Non-small-cell Lung Cancer Through Up-regulating LHX6 Expression,” Scientific Reports 7, no. 1 (2017): 781.

[527] T.-H. Wu, S.-Y. Chang, Y.-L. Shih, C.-F. Chian, H. Chang, and Y.-W. Lin, “Epigenetic Silencing of LMX1A Contributes to Cancer Progression in Lung Cancer Cells,” InternationaL Journal of Molecular Sciences 21, no. 15 (2020): 5425.

[528] W. Dong, L. Feng, Y. Xie, H. Zhang, and Y. Wu, “Hypermethylation-mediated Reduction of LMX1A Expression in Gastric Cancer,” Cancer Science 102, no. 2 (2011): 361–366.

[529] J. Kumar, “The Sine Oculis Homeobox (SIX) family of Transcription Factors as Regulators of Development and Disease,” Cellular and Molecular Life Sciences 66 (2009): 565–583.

[530] Q. Liu, A. Li, Y. Tian, et al., “The Expression Profile and Clinic Significance of the SIX family in Non-small Cell Lung Cancer,” Journal of Hematology & Oncology 9, no. 1 (2016): 1–13.

[531] M.-L. Mo, J. Okamoto, Z. Chen, et al., “Down-regulation of SIX3 Is Associated With Clinical Outcome in Lung Adenocarcinoma,” PLoS ONE 8, no. 8 (2013): e71816.

[532] Y. Du, H. Li, Y. Wang, Y. He, and G. Li, “DLX1 acts as a Novel Prognostic Biomarker Involved in Immune Cell Infiltration and Tumor Progression in Lung Adenocarcinoma,” PeerJ 12 (2024): e16823.

[533] Z. Wan, J. Wang, Q. Liu, D. Yang, P. Li, and L. Wang, “Knockdown of DLK4 Inhibits Non-small Cell Lung Cancer Tumor Growth by Downregulating CKS2,” Open Life Sciences 18, no. 1 (2023): 20220720.

[534] T. A. Rauch, Z. Wang, X. Wu, K. H. Kernstine, A. D. Riggs, and G. P. Pfeifer, “DNA Methylation Biomarkers for Lung Cancer,” Tumor Biology 33 (2012): 287–296.

[535] H. Harada, K. Miyamoto, Y. Yamashita, K. Taniyama, H. Ohdan, and M. Okada, “Methylated DLX4 Predicts Response to Pathologic Stage I Non-small Cell Lung Cancer Resection,” The Annals of Thoracic Surgery 99, no. 5 (2015): 1746–1754.

[536] F. Rivadeneira and A. G. Uitterlinden, “Osteoporosis Genes Identified by Genome-wide Association studies,” Genetics of Bone Biology and Skeletal Disease. (Elsevier, 2018): 377–395.

[537] J. Xu and J. R. Testa, “DLX5 (distal-less homeobox 5) promotes Tumor Cell Proliferation by Transcriptionally Regulating MYC,” Journal of Biological Chemistry 284, no. 31 (2009): 20593–20601.

[538] T. Kato, N. Sato, A. Takano, et al., “Activation of Placenta-specific Transcription Factor Distal-less Homeobox 5 Predicts Clinical Outcome in Primary Lung Cancer Patients,” Clinical Cancer Research 14, no. 8 (2008): 2363–2370.

[539] R. Wang, X. Chen, T. Xu, et al., “MiR-326 Regulates Cell Proliferation and Migration in Lung Cancer by Targeting phox2a and Is Regulated by HOTAIR,” American Journal of Cancer Research 6, no. 2 (2016): 173.

[540] L. Jiang, Z. Zuo, J. Lin, and C. Yang, “Orthodenticle Homeobox OTX1 Is a Potential Prognostic Biomarker for Bladder Cancer,” Bioengineered 12, no. 1 (2021): 6559–6571.

[541] C.-Y. Yang, L. Wang, D.-C. Mu, et al., “OTX1 is a Novel Regulator of Proliferation, Migration, Invasion and Apoptosis in Lung Adenocarcinoma,” European Review for Medical & Pharmacological Sciences 24, no. 18 (2020): 9497–9510.

[542] J. Liu, J. Liu, and X. Lu, “HOXA1 upregulation Is Associated With Poor Prognosis and Tumor Progression in Breast Cancer,” Experimental and Therapeutic Medicine 17, no. 3 (2019): 1896–1902.

[543] F. D. E. De Palma, J. G. Pol, V. Carbonnier, et al., “Epigenetic Regulation of HOXA2 Expression Affects Tumor Progression and Predicts Breast Cancer Patient Survival,” Cell Death & Differentiation 32, no. 4 (2025): 730–744.

[544] V. Raman, S. A. Martensen, D. Reisman, et al., “Compromised HOXA5 Function Can Limit p53 Expression in human Breast Tumours,” Nature 405, no. 6789 (2000): 974–978.

[545] I. Hussain, P. Deb, A. Chini, et al., “HOXA5 expression Is Elevated in Breast Cancer and Is Transcriptionally Regulated by Estradiol,” Frontiers in Genetics 11 (2020): 592436.

[546] Q. Xu, Q. Zhang, M. Dong, and Y. Yu, “MicroRNA-638 Inhibits the Progression of Breast Cancer Through Targeting HOXA9 and Suppressing Wnt/β-cadherin Pathway,” World Journal of Surgical Oncology 19, no. 1 (2021): 247.

[547] S. Bakkensen Bruun, R. Fredslund Andersen, J. Skov Madsen, et al., “Circulating Methylated HOXA9 Tumor DNA as a Biomarker for Mortality in Recurrent Breast Cancer: An Exploratory Study,” Oncology Letters 28, no. 6 (2024): 581.

[548] S. A. de Bessa Garcia, M. Araujo, T. Pereira, and R. Freitas, “HOXB7 overexpression Leads Triple-negative Breast Cancer Cells to a Less Aggressive Phenotype,” Biomedicines 9, no. 5 (2021): 515.

[549] H. Seki, T. Hayashida, H. Jinno, et al., “HOXB9 expression Promoting Tumor Cell Proliferation and Angiogenesis Is Associated With Clinical Outcomes in Breast Cancer Patients,” Annals of Surgical Oncology 19, no. 6 (2012): 1831–1840.

[550] M. Shah, R. Cardenas, B. Wang, et al., “HOXC8 regulates Self-renewal, Differentiation and Transformation of Breast Cancer Stem Cells,” Molecular Cancer 16, no. 1 (2017): 38.

[551] P. Sekar, J. N. Bharti, J. S. Nigam, A. Sharma, and P. B. Soni, “Evaluation of p53, HoxD10, and E-cadherin Status in Breast Cancer and Correlation With Histological Grade and Other Prognostic Factors,” Journal of Oncology 2014, no. 1 (2014): 702527.

[552] B. Osmond, C. O. Facey, C. Zhang, and B. M. Boman, “HOXA9 overexpression Contributes to Stem Cell Overpopulation That Drives Development and Growth of Colorectal Cancer,” International Journal of Molecular Sciences 23, no. 12 (2022): 6799.

[553] C. Qiao, W. Huang, J. Chen, et al., “IGF1-mediated HOXA13 Overexpression Promotes Colorectal Cancer Metastasis Through Upregulating ACLY and IGF1R,” Cell Death & Disease 12, no. 6 (2021): 564.

[554] W. Feng, W. Huang, J. Chen, et al., “CXCL12-mediated HOXB5 Overexpression Facilitates Colorectal Cancer Metastasis Through Transactivating CXCR4 and ITGB3,” Theranostics 11, no. 6 (2021): 2612.

[555] W.-T. Liao, D. Jiang, J. Yuan, et al., “HOXB7 as a Prognostic Factor and Mediator of Colorectal Cancer Progression,” Clinical Cancer Research 17, no. 11 (2011): 3569–3578.

[556] T. Wang, F. Lin, X. Sun, et al., “HOXB8 enhances the Proliferation and Metastasis of Colorectal Cancer Cells by Promoting EMT via STAT3 Activation,” Cancer Cell International 19, no. 1 (2019): 3.

[557] H. Wang, G. Liu, D. Shen, et al., “HOXA1 enhances the Cell Proliferation, Invasion and Metastasis of Prostate Cancer Cells,” Oncology Reports 34, no. 3 (2015): 1203–1210.

[558] M. Zhong, W. Xu, P. Tian, et al., “An Inherited Allele Confers Prostate Cancer Progression and Drug Resistance via RFX6/HOXA10-Orchestrated TGFβ Signaling,” Advanced Science 11, no. 32 (2024): 2401492.

[559] Y. Ma, R. Liu, P. Qi, et al., “HOXA13 promotes Prostate Cancer Metastasis by Inhibiting Ferroptosis via Upregulating SLC7A11 and SLC3A2,” Cellular Signalling 136 (2025): 112168.

[560] Y.-R. Kim, K.-J. Oh, R.-Y. Park, et al., “HOXB13 promotes Androgen Independent Growth of LNCaP Prostate Cancer Cells by the Activation of E2F Signaling,” Molecular Cancer 9, no. 1 (2010): 124.

[561] C. D. McCabe, D. D. Spyropoulos, D. Martin, and C. S. Moreno, “Genome-wide Analysis of the Homeobox C6 Transcriptional Network in Prostate Cancer,” Cancer Research 68, no. 6 (2008): 1988–1996.

[562] X. Song, T. Li, W. Zhou, et al., “CAF-derived Exosomal miR-196b-5p After Androgen Deprivation Therapy Promotes Epithelial-mesenchymal Transition in Prostate Cancer Cells Through HOXC8/NF-κB Signaling Pathway,” Biology Direct 20, no. 1 (2025): 80.

[563] M. Liang, Y. Sun, H.-L. Yang, B. Zhang, J. Wen, and B.-K. Shi, “DLX1, a Binding Protein of Beta-catenin, Promoted the Growth and Migration of Prostate Cancer Cells,” Experimental Cell Research 363, no. 1 (2018): 26–32.

[564] W. Chen, G. Wu, Y. Zhu, et al., “HOXA10 deteriorates Gastric Cancer Through Activating JAK1/STAT3 Signaling Pathway,” Cancer Management and Research 11 (2019): 6625–6635.

[565] Z. Qin and C. Zhou, “HOXA13 promotes Gastric Cancer Progression Partially via the FN1-mediated FAK/Src Axis,” Experimental Hematology & Oncology 11, no. 1 (2022): 7.

[566] C. Yuan, Y. Xie, X. Sheng, et al., “Role of HOXB7 in Promoting Gastric Cancer Progression and Oxaliplatin (L-OHP) Resistance,” International Journal of Clinical and Experimental Pathology 13, no. 6 (2020): 1381.

[567] C.-Y. Tsai, J. B. Liao, Y.-C. Lee, and Y.-F. Yang, “HOXC8 mediates Osteopontin Expression in Gastric Cancer Cells,” Journal of Cancer 14, no. 13 (2023): 2552.

[568] J. Zhang, N. Hou, D. Rao, Q. Chen, Z. Ning, and M. Lu, “HOXC12 promotes the Invasion and Migration of Gastric Cancer Cells by Upregulating SALL4 and Activating Wnt/β-catenin Signaling Pathway,” Discover Oncology 15, no. 1 (2024): 620.

[569] H. Zhu, W. Dai, J. Li, et al., “HOXD9 promotes the Growth, Invasion and Metastasis of Gastric Cancer Cells by Transcriptional Activation of RUFY3,” Journal of Experimental & Clinical Cancer Research 38, no. 1 (2019): 412.

[570] D. Chai, H. Du, K. Li, et al., “CDX2 and Reg IV Expression and Correlation in Gastric Cancer,” BMC Gastroenterology 21, no. 1 (2021): 92.

[571] D. Haria and H. Naora, “Homeobox Gene Deregulation: Impact on the Hallmarks of Cancer,” Cancer Hallmarks 1 (2013): 67–76.

[572] E. Martinou, G. Falgari, I. Bagwan, and A. M. Angelidi, “A Systematic Review on HOX Genes as Potential Biomarkers in Colorectal Cancer: An Emerging Role of HOXB9,” International Journal of Molecular Sciences 22, no. 24 (2021): 13429.

[573] R. Morgan, M. El-Tanani, K. D. Hunter, K. J. Harrington, and H. S. Pandha, “Targeting HOX/PBX Dimers in Cancer,” Oncotarget 8, no. 19 (2017): 32322.

[574] C. Y. Kim, Y. C. Kim, J. H. Oh, and M. H. Kim, “HOXA5 confers Tamoxifen Resistance via the PI3K/AKT Signaling Pathway in ER-positive Breast Cancer,” Journal of Cancer 12, no. 15 (2021): 4626.

[575] K. Jin, X. Kong, T. Shah, et al., “The HOXB7 Protein Renders Breast Cancer Cells Resistant to Tamoxifen Through Activation of the EGFR Pathway,” Proceedings of the National Academy of Sciences of the United States of America 109, no. 8 (2012): 2736–2741.

[576] J.-Y. Lee, H. Hur, H. J. Yun, et al., “HOXB5 promotes the Proliferation and Invasion of Breast Cancer Cells,” International Journal of Biological Sciences 11, no. 6 (2015): 701.

[577] F. Chen, G. Sun, and J. Peng, “RNAi-mediated HOXD3 Knockdown Inhibits Growth in human RKO Cells,” Oncology Reports 36, no. 4 (2016): 1793–1798.

[578] Y. Wu, G. Jiang, N. Zhang, et al., “HOXA9, PCDH17, POU4F2, and ONECUT2 as a Urinary Biomarker Combination for the Detection of Bladder Cancer in Chinese Patients With Hematuria,” European Urology Focus 6, no. 2 (2020): 284–291.

[579] S. Ghafouri-Fard, A. Aghabalazade, H. Shoorei, J. Majidpoor, M. Taheri, and M. Mokhtari, “The Impact of lncRNAs and miRNAs on Apoptosis in Lung Cancer,” Frontiers in Oncology 11 (2021): 714795.

[580] A. Paço, S. Aparecida de Bessa Garcia, J. Leitão Castro, A. R. Costa-Pinto, and R. Freitas, “Roles of the HOX Proteins in Cancer Invasion and Metastasis,” Cancers 13, no. 1 (2020): 10.

[581] D. B. Brotto, Á. D. D. Siena, I. I. de Barros, et al., “Contributions of HOX Genes to Cancer Hallmarks: Enrichment Pathway Analysis and Review,” Tumor Biology 42, no. 5 (2020): 1010428320918050.

[582] R. Morgan, K. Hunter, and H. S. Pandha, “Downstream of the HOX Genes: Explaining Conflicting Tumour Suppressor and Oncogenic Functions in Cancer,” International Journal of Cancer 150, no. 12 (2022): 1919–1932.

[583] L. B. Bennett, J. L. Schnabel, J. M. Kelchen, et al., “DNA Hypermethylation Accompanied by Transcriptional Repression in Follicular Lymphoma,” Genes, Chromosomes and Cancer 48, no. 9 (2009): 828–841.

[584] A. Avraham, J. Sandbank, N. Yarom, et al., “A Similar Cell-specific Pattern of HOXA Methylation in Normal and in Cancer Tissues,” Epigenetics 5, no. 1 (2010): 41–46.

[585] M. Abe, J. Hamada, and O. Takahashi, “Disordered Expression of HOX Genes in human Non-small Cell Lung Cancer,” Oncology Reports 15, no. 4 (2006): 797–802.

[586] S. Monterisi, P. Lo Riso, and K. Russo, “HOXB7 overexpression in Lung Cancer Is a Hallmark of Acquired Stem-Like Phenotype,” Oncogene 37, no. 26 (2018): 3575–3588.

[587] H. Huang, Z. Huo, J. Jiao, et al., “HOXC6 impacts Epithelial-mesenchymal Transition and the Immune Microenvironment Through Gene Transcription in Gliomas,” Cancer Cell International 22, no. 1 (2022): 170.

[588] H. Li, P. Gao, H. Chen, et al., “HOXC13 promotes Cell Proliferation, Metastasis and Glycolysis in Breast Cancer by Regulating DNMT3A,” Experimental and Therapeutic Medicine 26, no. 3 (2023): 1–11.

[589] Y. Deng, R. He, R. Zhang, et al., “The Expression of HOXA13 in Lung Adenocarcinoma and Its Clinical Significance: A Study Based on The Cancer Genome Atlas, Oncomine and Reverse Transcription‑Quantitative Polymerase Chain Reaction,” Oncology Letters 15, no. 6 (2018): 8556–8572.

[590] T. Ma, B. Yan, Y. Hu, and Q. Zhang, “HOXA10 promotion of HDAC1 Underpins the Development of Lung Adenocarcinoma Through the DNMT1-KLF4 Axis,” Journal of Experimental & Clinical Cancer Research 40 (2021): 1–14.

[591] M. Ratti, A. Lampis, M. Ghidini, et al., “MicroRNAs (miRNAs) and Long Non-coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps From Bench to Bedside,” Targeted Oncology 15 (2020): 261–278.

[592] N. Gao, Y. Li, J. Li, et al., “Long Non-coding RNAs: The Regulatory Mechanisms, Research Strategies, and Future Directions in Cancers,” Frontiers in Oncology 10 (2020): 598817.

[593] X.-H. Liu, Z.-L. Liu, M. Sun, J. Liu, Z.-X. Wang, and W. De, “The Long Non-coding RNA HOTAIR Indicates a Poor Prognosis and Promotes Metastasis in Non-small Cell Lung Cancer,” BMC Cancer 13 (2013): 1–10.

[594] R. Q. da Silvia Lima, C. F. M. Vasconcelos, J. P. A. Gomes, et al., “miRNA-21, an OncomiR That Regulates Cell Proliferation, Migration, Invasion and Therapy Response in Lung Cancer,” Pathology-Research and Practice 263 (2024): 155601.

[595] K.-L. Wu, Y.-M. Tsai, C.-T. Lien, P.-L. Kuo, and J.-Y. Hung, “The Roles of MicroRNA in Lung Cancer,” International Journal of Molecular Sciences 20, no. 7 (2019): 1611.

[596] D. H. Pozza, R. A. De Mello, R. L. Araujo, and V. Velcheti, “MicroRNAs in Lung Cancer Oncogenesis and Tumor Suppression: How It Can Improve the Clinical Practice?,” Current Genomics 21, no. 5 (2020): 372–381.

[597] N. Wan and J. Zheng, “MicroRNA‑891a‑5p Is a Novel Biomarker for Non‑Small Cell Lung Cancer and Targets HOXA5 to Regulate Tumor Cell Biological Function,” Oncology Letters 22, no. 1 (2021): 1–10.

[598] Q. Zhu, T. Lv, Y. Wu, X. Shi, H. Liu, and Y. Song, “Long Non-coding RNA 00312 Regulated by HOXA 5 Inhibits Tumour Proliferation and Promotes Apoptosis in Non-small Cell Lung Cancer,” Journal of Cellular and Molecular Medicine 21, no. 9 (2017): 2184–2198.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.